GRCh37	EGFR	In_Frame_Del	CRUK0003-SU_T1.R1			c.2234_2234delins-GGAATTAAGAGAAGC	7	55242464	55242464	A	-GGAATTAAGAGAAGC	-GGAATTAAGAGAAGC	0.24510717614165897	LUAD	True	True	True	Likely Gain-of-function	15329413;18000506;15118125;34526717;19536777;18458038;15118073;22019513;23566546;23559152;24457318;22760226;23749122;17192902	Likely Oncogenic	Erlotinib,Osimertinib+Chemotherapy,Erlotinib+Ramucirumab,Afatinib,Gefitinib,Osimertinib,Dacomitinib	Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		22285168;27987585;29151359;37937763;31751012;30659024;23816960;22452895;25589191;20022809;19692680;21670455;22370314;31682542;20573926;29864379;28958502;37879444;37689979;38369013;31661465;34548309;30057690;34084213;38924756;34028784;37710001										
GRCh37	EGFR	In_Frame_Del	CRUK0003-SU_T1.R2			c.2234_2234delins-GGAATTAAGAGAAGC	7	55242464	55242464	A	-GGAATTAAGAGAAGC	-GGAATTAAGAGAAGC	0.235537190082645	LUAD	True	True	True	Likely Gain-of-function	15329413;18000506;15118125;34526717;19536777;18458038;15118073;22019513;23566546;23559152;24457318;22760226;23749122;17192902	Likely Oncogenic	Erlotinib,Osimertinib+Chemotherapy,Erlotinib+Ramucirumab,Afatinib,Gefitinib,Osimertinib,Dacomitinib	Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		22285168;27987585;29151359;37937763;31751012;30659024;23816960;22452895;25589191;20022809;19692680;21670455;22370314;31682542;20573926;29864379;28958502;37879444;37689979;38369013;31661465;34548309;30057690;34084213;38924756;34028784;37710001										
GRCh37	EGFR	In_Frame_Del	CRUK0003-SU_T1.R3			c.2234_2234delins-GGAATTAAGAGAAGC	7	55242464	55242464	A	-GGAATTAAGAGAAGC	-GGAATTAAGAGAAGC	0.17604166666666698	LUAD	True	True	True	Likely Gain-of-function	15329413;18000506;15118125;34526717;19536777;18458038;15118073;22019513;23566546;23559152;24457318;22760226;23749122;17192902	Likely Oncogenic	Erlotinib,Osimertinib+Chemotherapy,Erlotinib+Ramucirumab,Afatinib,Gefitinib,Osimertinib,Dacomitinib	Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		22285168;27987585;29151359;37937763;31751012;30659024;23816960;22452895;25589191;20022809;19692680;21670455;22370314;31682542;20573926;29864379;28958502;37879444;37689979;38369013;31661465;34548309;30057690;34084213;38924756;34028784;37710001										
GRCh37	EGFR	In_Frame_Del	CRUK0003-SU_T1.R4			c.2234_2234delins-GGAATTAAGAGAAGC	7	55242464	55242464	A	-GGAATTAAGAGAAGC	-GGAATTAAGAGAAGC	0.23169750603378897	LUAD	True	True	True	Likely Gain-of-function	15329413;18000506;15118125;34526717;19536777;18458038;15118073;22019513;23566546;23559152;24457318;22760226;23749122;17192902	Likely Oncogenic	Erlotinib,Osimertinib+Chemotherapy,Erlotinib+Ramucirumab,Afatinib,Gefitinib,Osimertinib,Dacomitinib	Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		22285168;27987585;29151359;37937763;31751012;30659024;23816960;22452895;25589191;20022809;19692680;21670455;22370314;31682542;20573926;29864379;28958502;37879444;37689979;38369013;31661465;34548309;30057690;34084213;38924756;34028784;37710001										
GRCh37	EGFR	In_Frame_Del	CRUK0003-SU_T1.R5			c.2234_2234delins-GGAATTAAGAGAAGC	7	55242464	55242464	A	-GGAATTAAGAGAAGC	-GGAATTAAGAGAAGC	0.0368968779564806	LUAD	True	True	True	Likely Gain-of-function	15329413;18000506;15118125;34526717;19536777;18458038;15118073;22019513;23566546;23559152;24457318;22760226;23749122;17192902	Likely Oncogenic	Erlotinib,Osimertinib+Chemotherapy,Erlotinib+Ramucirumab,Afatinib,Gefitinib,Osimertinib,Dacomitinib	Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		22285168;27987585;29151359;37937763;31751012;30659024;23816960;22452895;25589191;20022809;19692680;21670455;22370314;31682542;20573926;29864379;28958502;37879444;37689979;38369013;31661465;34548309;30057690;34084213;38924756;34028784;37710001										
GRCh37	EGFR	In_Frame_Del	CRUK0003-SU_T1.R6			c.2234_2234delins-GGAATTAAGAGAAGC	7	55242464	55242464	A	-GGAATTAAGAGAAGC	-GGAATTAAGAGAAGC	0.21206743566992	LUAD	True	True	True	Likely Gain-of-function	15329413;18000506;15118125;34526717;19536777;18458038;15118073;22019513;23566546;23559152;24457318;22760226;23749122;17192902	Likely Oncogenic	Erlotinib,Osimertinib+Chemotherapy,Erlotinib+Ramucirumab,Afatinib,Gefitinib,Osimertinib,Dacomitinib	Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		22285168;27987585;29151359;37937763;31751012;30659024;23816960;22452895;25589191;20022809;19692680;21670455;22370314;31682542;20573926;29864379;28958502;37879444;37689979;38369013;31661465;34548309;30057690;34084213;38924756;34028784;37710001										
GRCh37	EGFR	In_Frame_Del	CRUK0003-SU_FLN1			c.2234_2234delins-GGAATTAAGAGAAGC	7	55242464	55242464	A	-GGAATTAAGAGAAGC	-GGAATTAAGAGAAGC	0.228813559322034	LUAD	True	True	True	Likely Gain-of-function	15329413;18000506;15118125;34526717;19536777;18458038;15118073;22019513;23566546;23559152;24457318;22760226;23749122;17192902	Likely Oncogenic	Erlotinib,Osimertinib+Chemotherapy,Erlotinib+Ramucirumab,Afatinib,Gefitinib,Osimertinib,Dacomitinib	Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		22285168;27987585;29151359;37937763;31751012;30659024;23816960;22452895;25589191;20022809;19692680;21670455;22370314;31682542;20573926;29864379;28958502;37879444;37689979;38369013;31661465;34548309;30057690;34084213;38924756;34028784;37710001										
GRCh37	EGFR	Missense	CRUK0004-SU_T1.R1	p.G719A	p.G719A	c.G2156C	7	55241708	55241708	G	C	C	0.287671232876712	LUAD	True	True	True	Gain-of-function	27294619;21531810;31825714;31931137;26206867;34526717	Oncogenic	Afatinib	Amivantamab+Chemotherapy,Dacomitinib,Osimertinib,Erlotinib,Gefitinib	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		23816960;22452895;25589191;37879444;35770100;37991747;31825714;25668120;37689979;38369013;31661465;34548309;30057690;34084213;Cho et al. Abstract #8516, ASCO 2024.(https://ascopubs.org/doi/pdf/10.1200/JCO.2024.42.16_suppl.8516)										
GRCh37	EGFR	Missense	CRUK0004-SU_T1.R2	p.G719A	p.G719A	c.G2156C	7	55241708	55241708	G	C	C	0.0774907749077491	LUAD	True	True	True	Gain-of-function	27294619;21531810;31825714;31931137;26206867;34526717	Oncogenic	Afatinib	Amivantamab+Chemotherapy,Dacomitinib,Osimertinib,Erlotinib,Gefitinib	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		23816960;22452895;25589191;37879444;35770100;37991747;31825714;25668120;37689979;38369013;31661465;34548309;30057690;34084213;Cho et al. Abstract #8516, ASCO 2024.(https://ascopubs.org/doi/pdf/10.1200/JCO.2024.42.16_suppl.8516)										
GRCh37	EGFR	Missense	CRUK0004-SU_T1.R3	p.G719A	p.G719A	c.G2156C	7	55241708	55241708	G	C	C	0.212543554006969	LUAD	True	True	True	Gain-of-function	27294619;21531810;31825714;31931137;26206867;34526717	Oncogenic	Afatinib	Amivantamab+Chemotherapy,Dacomitinib,Osimertinib,Erlotinib,Gefitinib	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		23816960;22452895;25589191;37879444;35770100;37991747;31825714;25668120;37689979;38369013;31661465;34548309;30057690;34084213;Cho et al. Abstract #8516, ASCO 2024.(https://ascopubs.org/doi/pdf/10.1200/JCO.2024.42.16_suppl.8516)										
GRCh37	EGFR	Missense	CRUK0004-SU_T1.R4	p.G719A	p.G719A	c.G2156C	7	55241708	55241708	G	C	C	0.3645833333333329	LUAD	True	True	True	Gain-of-function	27294619;21531810;31825714;31931137;26206867;34526717	Oncogenic	Afatinib	Amivantamab+Chemotherapy,Dacomitinib,Osimertinib,Erlotinib,Gefitinib	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		23816960;22452895;25589191;37879444;35770100;37991747;31825714;25668120;37689979;38369013;31661465;34548309;30057690;34084213;Cho et al. Abstract #8516, ASCO 2024.(https://ascopubs.org/doi/pdf/10.1200/JCO.2024.42.16_suppl.8516)										
GRCh37	EGFR	Missense	CRUK0004-BP_LN1	p.G719A	p.G719A	c.G2156C	7	55241708	55241708	G	C	C	0.414772727272727	LUAD	True	True	True	Gain-of-function	27294619;21531810;31825714;31931137;26206867;34526717	Oncogenic	Afatinib	Amivantamab+Chemotherapy,Dacomitinib,Osimertinib,Erlotinib,Gefitinib	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		23816960;22452895;25589191;37879444;35770100;37991747;31825714;25668120;37689979;38369013;31661465;34548309;30057690;34084213;Cho et al. Abstract #8516, ASCO 2024.(https://ascopubs.org/doi/pdf/10.1200/JCO.2024.42.16_suppl.8516)										
GRCh37	BRAF	Missense	CRUK0005-SU_T1.R1	p.G466E	p.G466E	c.G1397A	7	140481411	140481411	C	T	T	0.142602495543672	LUAD	True	True	True	Gain-of-function	31515458;27790118;27523909;15046639;28783719;15035987;24446311;28481359	Oncogenic																					
GRCh37	BRAF	Missense	CRUK0005-SU_T1.R2	p.G466E	p.G466E	c.G1397A	7	140481411	140481411	C	T	T	0.14902506963788298	LUAD	True	True	True	Gain-of-function	31515458;27790118;27523909;15046639;28783719;15035987;24446311;28481359	Oncogenic																					
GRCh37	BRAF	Missense	CRUK0005-SU_T1.R3	p.G466E	p.G466E	c.G1397A	7	140481411	140481411	C	T	T	0.19496855345911998	LUAD	True	True	True	Gain-of-function	31515458;27790118;27523909;15046639;28783719;15035987;24446311;28481359	Oncogenic																					
GRCh37	BRAF	Missense	CRUK0005-SU_T1.R4	p.G466E	p.G466E	c.G1397A	7	140481411	140481411	C	T	T	0.193293885601578	LUAD	True	True	True	Gain-of-function	31515458;27790118;27523909;15046639;28783719;15035987;24446311;28481359	Oncogenic																					
GRCh37	EGFR	In_Frame_Del	CRUK0007-SU_T1.R1			c.2234_2234delins-GGAATTAAGAGAAGC	7	55242464	55242464	A	-GGAATTAAGAGAAGC	-GGAATTAAGAGAAGC	0.0712195121951219	LUAD	True	True	True	Likely Gain-of-function	15329413;18000506;15118125;34526717;19536777;18458038;15118073;22019513;23566546;23559152;24457318;22760226;23749122;17192902	Likely Oncogenic	Erlotinib,Osimertinib+Chemotherapy,Erlotinib+Ramucirumab,Afatinib,Gefitinib,Osimertinib,Dacomitinib	Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		22285168;27987585;29151359;37937763;31751012;30659024;23816960;22452895;25589191;20022809;19692680;21670455;22370314;31682542;20573926;29864379;28958502;37879444;37689979;38369013;31661465;34548309;30057690;34084213;38924756;34028784;37710001										
GRCh37	EGFR	In_Frame_Del	CRUK0007-SU_T1.R2			c.2234_2234delins-GGAATTAAGAGAAGC	7	55242464	55242464	A	-GGAATTAAGAGAAGC	-GGAATTAAGAGAAGC	0.15776699029126198	LUAD	True	True	True	Likely Gain-of-function	15329413;18000506;15118125;34526717;19536777;18458038;15118073;22019513;23566546;23559152;24457318;22760226;23749122;17192902	Likely Oncogenic	Erlotinib,Osimertinib+Chemotherapy,Erlotinib+Ramucirumab,Afatinib,Gefitinib,Osimertinib,Dacomitinib	Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		22285168;27987585;29151359;37937763;31751012;30659024;23816960;22452895;25589191;20022809;19692680;21670455;22370314;31682542;20573926;29864379;28958502;37879444;37689979;38369013;31661465;34548309;30057690;34084213;38924756;34028784;37710001										
GRCh37	BRAF	Missense	CRUK0009-SU_T1.R1	p.K601E	p.K601E	c.A1801G	7	140453134	140453134	T	C	C	0.535714285714286	LUAD	True	True	True	Gain-of-function	20179705;26343582;35630083;34590045;28783719;22608338;26643848;31515458;22798288;29320312;28344857;30559419;23248257	Likely Oncogenic				Trametinib	Plixorafenib			LEVEL_3B	LEVEL_3B		28344857;24933606;23248257;22798288;29903896;26466569;28659148;28783719;30559419;Janku et al. Abstract# B176, AACR-NCI-EORTC 2017.(http://mct.aacrjournals.org/content/17/1_Supplement/B176);Fuente et al. Abstract# 3006, J. Clin. Oncol. 2023, Vol 41, Suppl 16.(https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.3006)										
GRCh37	BRAF	Missense	CRUK0009-SU_T1.R2	p.K601E	p.K601E	c.A1801G	7	140453134	140453134	T	C	C	0.24675324675324697	LUAD	True	True	True	Gain-of-function	20179705;26343582;35630083;34590045;28783719;22608338;26643848;31515458;22798288;29320312;28344857;30559419;23248257	Likely Oncogenic				Trametinib	Plixorafenib			LEVEL_3B	LEVEL_3B		28344857;24933606;23248257;22798288;29903896;26466569;28659148;28783719;30559419;Janku et al. Abstract# B176, AACR-NCI-EORTC 2017.(http://mct.aacrjournals.org/content/17/1_Supplement/B176);Fuente et al. Abstract# 3006, J. Clin. Oncol. 2023, Vol 41, Suppl 16.(https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.3006)										
GRCh37	BRAF	Missense	CRUK0009-SU_T1.R3	p.K601E	p.K601E	c.A1801G	7	140453134	140453134	T	C	C	0.459259259259259	LUAD	True	True	True	Gain-of-function	20179705;26343582;35630083;34590045;28783719;22608338;26643848;31515458;22798288;29320312;28344857;30559419;23248257	Likely Oncogenic				Trametinib	Plixorafenib			LEVEL_3B	LEVEL_3B		28344857;24933606;23248257;22798288;29903896;26466569;28659148;28783719;30559419;Janku et al. Abstract# B176, AACR-NCI-EORTC 2017.(http://mct.aacrjournals.org/content/17/1_Supplement/B176);Fuente et al. Abstract# 3006, J. Clin. Oncol. 2023, Vol 41, Suppl 16.(https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.3006)										
GRCh37	BRAF	Missense	CRUK0009-SU_T1.R4	p.K601E	p.K601E	c.A1801G	7	140453134	140453134	T	C	C	0.41011235955056197	LUAD	True	True	True	Gain-of-function	20179705;26343582;35630083;34590045;28783719;22608338;26643848;31515458;22798288;29320312;28344857;30559419;23248257	Likely Oncogenic				Trametinib	Plixorafenib			LEVEL_3B	LEVEL_3B		28344857;24933606;23248257;22798288;29903896;26466569;28659148;28783719;30559419;Janku et al. Abstract# B176, AACR-NCI-EORTC 2017.(http://mct.aacrjournals.org/content/17/1_Supplement/B176);Fuente et al. Abstract# 3006, J. Clin. Oncol. 2023, Vol 41, Suppl 16.(https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.3006)										
GRCh37	BRAF	Missense	CRUK0009-SU_FLN1	p.K601E	p.K601E	c.A1801G	7	140453134	140453134	T	C	C	0.25	LUAD	True	True	True	Gain-of-function	20179705;26343582;35630083;34590045;28783719;22608338;26643848;31515458;22798288;29320312;28344857;30559419;23248257	Likely Oncogenic				Trametinib	Plixorafenib			LEVEL_3B	LEVEL_3B		28344857;24933606;23248257;22798288;29903896;26466569;28659148;28783719;30559419;Janku et al. Abstract# B176, AACR-NCI-EORTC 2017.(http://mct.aacrjournals.org/content/17/1_Supplement/B176);Fuente et al. Abstract# 3006, J. Clin. Oncol. 2023, Vol 41, Suppl 16.(https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.3006)										
GRCh37	EGFR	In_Frame_Del	CRUK0010-SU_T1.R1			c.2236_2236delins-AATTAAGAGAAGCAACAT	7	55242466	55242466	G	-AATTAAGAGAAGCAACAT	-AATTAAGAGAAGCAACAT	0.24738219895288002	LUAD	True	True	True	Likely Gain-of-function	15329413;18000506;15118125;34526717;19536777;18458038;15118073;22019513;23566546;23559152;24457318;22760226;23749122;17192902	Likely Oncogenic	Erlotinib,Osimertinib+Chemotherapy,Erlotinib+Ramucirumab,Afatinib,Gefitinib,Osimertinib,Dacomitinib	Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		22285168;27987585;29151359;37937763;31751012;30659024;23816960;22452895;25589191;20022809;19692680;21670455;22370314;31682542;20573926;29864379;28958502;37879444;37689979;38369013;31661465;34548309;30057690;34084213;38924756;34028784;37710001										
GRCh37	EGFR	In_Frame_Del	CRUK0010-SU_T1.R2			c.2236_2236delins-AATTAAGAGAAGCAACAT	7	55242466	55242466	G	-AATTAAGAGAAGCAACAT	-AATTAAGAGAAGCAACAT	0.167293233082707	LUAD	True	True	True	Likely Gain-of-function	15329413;18000506;15118125;34526717;19536777;18458038;15118073;22019513;23566546;23559152;24457318;22760226;23749122;17192902	Likely Oncogenic	Erlotinib,Osimertinib+Chemotherapy,Erlotinib+Ramucirumab,Afatinib,Gefitinib,Osimertinib,Dacomitinib	Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		22285168;27987585;29151359;37937763;31751012;30659024;23816960;22452895;25589191;20022809;19692680;21670455;22370314;31682542;20573926;29864379;28958502;37879444;37689979;38369013;31661465;34548309;30057690;34084213;38924756;34028784;37710001										
GRCh37	EGFR	In_Frame_Del	CRUK0010-BR_LN1			c.2236_2236delins-AATTAAGAGAAGCAACAT	7	55242466	55242466	G	-AATTAAGAGAAGCAACAT	-AATTAAGAGAAGCAACAT	0.106451612903226	LUAD	True	True	True	Likely Gain-of-function	15329413;18000506;15118125;34526717;19536777;18458038;15118073;22019513;23566546;23559152;24457318;22760226;23749122;17192902	Likely Oncogenic	Erlotinib,Osimertinib+Chemotherapy,Erlotinib+Ramucirumab,Afatinib,Gefitinib,Osimertinib,Dacomitinib	Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		22285168;27987585;29151359;37937763;31751012;30659024;23816960;22452895;25589191;20022809;19692680;21670455;22370314;31682542;20573926;29864379;28958502;37879444;37689979;38369013;31661465;34548309;30057690;34084213;38924756;34028784;37710001										
GRCh37	EGFR	In_Frame_Del	CRUK0010-BR_LN2			c.2236_2236delins-AATTAAGAGAAGCAACAT	7	55242466	55242466	G	-AATTAAGAGAAGCAACAT	-AATTAAGAGAAGCAACAT	0.0849514563106796	LUAD	True	True	True	Likely Gain-of-function	15329413;18000506;15118125;34526717;19536777;18458038;15118073;22019513;23566546;23559152;24457318;22760226;23749122;17192902	Likely Oncogenic	Erlotinib,Osimertinib+Chemotherapy,Erlotinib+Ramucirumab,Afatinib,Gefitinib,Osimertinib,Dacomitinib	Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		22285168;27987585;29151359;37937763;31751012;30659024;23816960;22452895;25589191;20022809;19692680;21670455;22370314;31682542;20573926;29864379;28958502;37879444;37689979;38369013;31661465;34548309;30057690;34084213;38924756;34028784;37710001										
GRCh37	EGFR	In_Frame_Del	CRUK0010-BR_LN3			c.2236_2236delins-AATTAAGAGAAGCAACAT	7	55242466	55242466	G	-AATTAAGAGAAGCAACAT	-AATTAAGAGAAGCAACAT	0.110151187904968	LUAD	True	True	True	Likely Gain-of-function	15329413;18000506;15118125;34526717;19536777;18458038;15118073;22019513;23566546;23559152;24457318;22760226;23749122;17192902	Likely Oncogenic	Erlotinib,Osimertinib+Chemotherapy,Erlotinib+Ramucirumab,Afatinib,Gefitinib,Osimertinib,Dacomitinib	Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		22285168;27987585;29151359;37937763;31751012;30659024;23816960;22452895;25589191;20022809;19692680;21670455;22370314;31682542;20573926;29864379;28958502;37879444;37689979;38369013;31661465;34548309;30057690;34084213;38924756;34028784;37710001										
GRCh37	EGFR	In_Frame_Del	CRUK0010-SU_FLN1			c.2236_2236delins-AATTAAGAGAAGCAACAT	7	55242466	55242466	G	-AATTAAGAGAAGCAACAT	-AATTAAGAGAAGCAACAT	0.10491071428571401	LUAD	True	True	True	Likely Gain-of-function	15329413;18000506;15118125;34526717;19536777;18458038;15118073;22019513;23566546;23559152;24457318;22760226;23749122;17192902	Likely Oncogenic	Erlotinib,Osimertinib+Chemotherapy,Erlotinib+Ramucirumab,Afatinib,Gefitinib,Osimertinib,Dacomitinib	Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		22285168;27987585;29151359;37937763;31751012;30659024;23816960;22452895;25589191;20022809;19692680;21670455;22370314;31682542;20573926;29864379;28958502;37879444;37689979;38369013;31661465;34548309;30057690;34084213;38924756;34028784;37710001										
GRCh37	KRAS	Missense	CRUK0011-SU_T1.R1	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.151648351648352	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0011-SU_T1.R2	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.26262626262626304	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0011-SU_T1.R3	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.315420560747664	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	EGFR	In_Frame_Del	CRUK0012-SU_T1.R1			c.2237_2237delins-ATTAAGAGAAGC	7	55242467	55242467	A	-ATTAAGAGAAGC	-ATTAAGAGAAGC	0.13855421686747	LUAD	True	True	True	Likely Gain-of-function	15329413;18000506;15118125;34526717;19536777;18458038;15118073;22019513;23566546;23559152;24457318;22760226;23749122;17192902	Likely Oncogenic	Erlotinib,Osimertinib+Chemotherapy,Erlotinib+Ramucirumab,Afatinib,Gefitinib,Osimertinib,Dacomitinib	Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		22285168;27987585;29151359;37937763;31751012;30659024;23816960;22452895;25589191;20022809;19692680;21670455;22370314;31682542;20573926;29864379;28958502;37879444;37689979;38369013;31661465;34548309;30057690;34084213;38924756;34028784;37710001										
GRCh37	EGFR	In_Frame_Del	CRUK0012-SU_T1.R2			c.2237_2237delins-ATTAAGAGAAGC	7	55242467	55242467	A	-ATTAAGAGAAGC	-ATTAAGAGAAGC	0.112903225806452	LUAD	True	True	True	Likely Gain-of-function	15329413;18000506;15118125;34526717;19536777;18458038;15118073;22019513;23566546;23559152;24457318;22760226;23749122;17192902	Likely Oncogenic	Erlotinib,Osimertinib+Chemotherapy,Erlotinib+Ramucirumab,Afatinib,Gefitinib,Osimertinib,Dacomitinib	Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		22285168;27987585;29151359;37937763;31751012;30659024;23816960;22452895;25589191;20022809;19692680;21670455;22370314;31682542;20573926;29864379;28958502;37879444;37689979;38369013;31661465;34548309;30057690;34084213;38924756;34028784;37710001										
GRCh37	KRAS	Missense	CRUK0014-SU_T1.R1	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.31288343558282206	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0014-SU_T1.R2	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.141914191419142	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	EGFR	In_Frame_Ins	CRUK0015-SU_T1.R1	p.A767delinsASVS	p.A767delinsASVS	c.2299_2300insCCAGCGTGT	7	55249001	55249001	-	CCAGCGTGT	CCAGCGTGT	0.20512820512820498	LUAD	True	True	False	Gain-of-function	23371856;19536777;24353160;21764376;18676761;23912954;23749122;15897572;17686547	Oncogenic	Amivantamab,Amivantamab+Chemotherapy		Poziotinib,CLN-081			Erlotinib,Gefitinib,Afatinib		LEVEL_R1	LEVEL_1	LEVEL_R1	23371856;24065731;19536777;24353160;21764376;18676761;24893891;23328547;15897572;17686547;37870976;32414908;34339292;35820397;27188206;29686424;Heymach et al. Abstract# OA02.06, WCLC 2018.(http://www.jto.org/article/S1556-0864(17)30520-8/fulltext);31467113;Yu et al. Abstract# 9007, ASCO 2022.(https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.9007)										
GRCh37	EGFR	In_Frame_Ins	CRUK0015-SU_T1.R2	p.A767delinsASVS	p.A767delinsASVS	c.2299_2300insCCAGCGTGT	7	55249001	55249001	-	CCAGCGTGT	CCAGCGTGT	0.18103448275862102	LUAD	True	True	False	Gain-of-function	23371856;19536777;24353160;21764376;18676761;23912954;23749122;15897572;17686547	Oncogenic	Amivantamab,Amivantamab+Chemotherapy		Poziotinib,CLN-081			Erlotinib,Gefitinib,Afatinib		LEVEL_R1	LEVEL_1	LEVEL_R1	23371856;24065731;19536777;24353160;21764376;18676761;24893891;23328547;15897572;17686547;37870976;32414908;34339292;35820397;27188206;29686424;Heymach et al. Abstract# OA02.06, WCLC 2018.(http://www.jto.org/article/S1556-0864(17)30520-8/fulltext);31467113;Yu et al. Abstract# 9007, ASCO 2022.(https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.9007)										
GRCh37	KRAS	Missense	CRUK0017-SU_T1.R2	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.13221153846153802	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0017-SU_T1.R3	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.201581027667984	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0017-SU_T1.R4	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.0617283950617284	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0018-SU_T1.R1	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.21164021164021202	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0018-SU_T1.R2	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.38125	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0018-SU_T1.R3	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.165311653116531	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0018-SU_T1.R4	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.161290322580645	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	EGFR	In_Frame_Del	CRUK0019-SU_T1.R1			c.2239_2239delins-TAAGAGAAGCAACATCTC	7	55242469	55242469	T	-TAAGAGAAGCAACATCTC	-TAAGAGAAGCAACATCTC	0.1	LUAD	True	True	True	Likely Gain-of-function	15329413;18000506;15118125;34526717;19536777;18458038;15118073;22019513;23566546;23559152;24457318;22760226;23749122;17192902	Likely Oncogenic	Erlotinib,Osimertinib+Chemotherapy,Erlotinib+Ramucirumab,Afatinib,Gefitinib,Osimertinib,Dacomitinib	Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		22285168;27987585;29151359;37937763;31751012;30659024;23816960;22452895;25589191;20022809;19692680;21670455;22370314;31682542;20573926;29864379;28958502;37879444;37689979;38369013;31661465;34548309;30057690;34084213;38924756;34028784;37710001										
GRCh37	EGFR	In_Frame_Del	CRUK0019-SU_T1.R2			c.2239_2239delins-TAAGAGAAGCAACATCTC	7	55242469	55242469	T	-TAAGAGAAGCAACATCTC	-TAAGAGAAGCAACATCTC	0.22751322751322797	LUAD	True	True	True	Likely Gain-of-function	15329413;18000506;15118125;34526717;19536777;18458038;15118073;22019513;23566546;23559152;24457318;22760226;23749122;17192902	Likely Oncogenic	Erlotinib,Osimertinib+Chemotherapy,Erlotinib+Ramucirumab,Afatinib,Gefitinib,Osimertinib,Dacomitinib	Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		22285168;27987585;29151359;37937763;31751012;30659024;23816960;22452895;25589191;20022809;19692680;21670455;22370314;31682542;20573926;29864379;28958502;37879444;37689979;38369013;31661465;34548309;30057690;34084213;38924756;34028784;37710001										
GRCh37	EGFR	Missense	CRUK0021-SU_T1.R1	p.L858R	p.L858R	c.T2573G	7	55259515	55259515	T	G	G	0.8177309361438309	LUAD	True	True	True	Gain-of-function	15329413;15118073;15118125;34526717	Oncogenic	Erlotinib,Osimertinib+Chemotherapy,Erlotinib+Ramucirumab,Afatinib,Gefitinib,Osimertinib,Dacomitinib	Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		22285168;27987585;29151359;37937763;31751012;30659024;23816960;22452895;25589191;20022809;19692680;21670455;22370314;31682542;20573926;29864379;28958502;37879444;37689979;38369013;31661465;34548309;30057690;34084213;38924756;34028784;37710001										
GRCh37	EGFR	Missense	CRUK0021-SU_T1.R2	p.L858R	p.L858R	c.T2573G	7	55259515	55259515	T	G	G	0.802431610942249	LUAD	True	True	True	Gain-of-function	15329413;15118073;15118125;34526717	Oncogenic	Erlotinib,Osimertinib+Chemotherapy,Erlotinib+Ramucirumab,Afatinib,Gefitinib,Osimertinib,Dacomitinib	Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		22285168;27987585;29151359;37937763;31751012;30659024;23816960;22452895;25589191;20022809;19692680;21670455;22370314;31682542;20573926;29864379;28958502;37879444;37689979;38369013;31661465;34548309;30057690;34084213;38924756;34028784;37710001										
GRCh37	EGFR	Missense	CRUK0022-SU_T1.R1	p.L858R	p.L858R	c.T2573G	7	55259515	55259515	T	G	G	0.3917525773195879	LUAD	True	True	True	Gain-of-function	15329413;15118073;15118125;34526717	Oncogenic	Erlotinib,Osimertinib+Chemotherapy,Erlotinib+Ramucirumab,Afatinib,Gefitinib,Osimertinib,Dacomitinib	Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		22285168;27987585;29151359;37937763;31751012;30659024;23816960;22452895;25589191;20022809;19692680;21670455;22370314;31682542;20573926;29864379;28958502;37879444;37689979;38369013;31661465;34548309;30057690;34084213;38924756;34028784;37710001										
GRCh37	EGFR	Missense	CRUK0022-SU_T1.R2	p.L858R	p.L858R	c.T2573G	7	55259515	55259515	T	G	G	0.4	LUAD	True	True	True	Gain-of-function	15329413;15118073;15118125;34526717	Oncogenic	Erlotinib,Osimertinib+Chemotherapy,Erlotinib+Ramucirumab,Afatinib,Gefitinib,Osimertinib,Dacomitinib	Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		22285168;27987585;29151359;37937763;31751012;30659024;23816960;22452895;25589191;20022809;19692680;21670455;22370314;31682542;20573926;29864379;28958502;37879444;37689979;38369013;31661465;34548309;30057690;34084213;38924756;34028784;37710001										
GRCh37	EGFR	Missense	CRUK0022-SU_FLN1	p.L858R	p.L858R	c.T2573G	7	55259515	55259515	T	G	G	0.36820083682008403	LUAD	True	True	True	Gain-of-function	15329413;15118073;15118125;34526717	Oncogenic	Erlotinib,Osimertinib+Chemotherapy,Erlotinib+Ramucirumab,Afatinib,Gefitinib,Osimertinib,Dacomitinib	Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		22285168;27987585;29151359;37937763;31751012;30659024;23816960;22452895;25589191;20022809;19692680;21670455;22370314;31682542;20573926;29864379;28958502;37879444;37689979;38369013;31661465;34548309;30057690;34084213;38924756;34028784;37710001										
GRCh37	KRAS	Missense	CRUK0023-SU_T1.R1	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.22453222453222502	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0023-SU_T1.R2	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.21468926553672302	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0023-SU_T1.R3	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.22670807453416197	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0023-SU_T1.R4	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.122516556291391	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0025-SU_T1.R1	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.46274509803921604	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0025-SU_T1.R2	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.5972602739726031	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0025-SU_T1.R3	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.32915360501567403	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	EGFR	Missense	CRUK0026-SU_T1.R1	p.L858R	p.L858R	c.T2573G	7	55259515	55259515	T	G	G	0.198250728862974	LUAD	True	True	True	Gain-of-function	15329413;15118073;15118125;34526717	Oncogenic	Erlotinib,Osimertinib+Chemotherapy,Erlotinib+Ramucirumab,Afatinib,Gefitinib,Osimertinib,Dacomitinib	Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		22285168;27987585;29151359;37937763;31751012;30659024;23816960;22452895;25589191;20022809;19692680;21670455;22370314;31682542;20573926;29864379;28958502;37879444;37689979;38369013;31661465;34548309;30057690;34084213;38924756;34028784;37710001										
GRCh37	EGFR	Missense	CRUK0026-SU_T1.R2	p.L858R	p.L858R	c.T2573G	7	55259515	55259515	T	G	G	0.239782016348774	LUAD	True	True	True	Gain-of-function	15329413;15118073;15118125;34526717	Oncogenic	Erlotinib,Osimertinib+Chemotherapy,Erlotinib+Ramucirumab,Afatinib,Gefitinib,Osimertinib,Dacomitinib	Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		22285168;27987585;29151359;37937763;31751012;30659024;23816960;22452895;25589191;20022809;19692680;21670455;22370314;31682542;20573926;29864379;28958502;37879444;37689979;38369013;31661465;34548309;30057690;34084213;38924756;34028784;37710001										
GRCh37	KRAS	Missense	CRUK0027-SU_T1.R1	p.G12A	p.G12A	c.G35C	12	25398284	25398284	C	G	G	0.17204301075268802	LUAD	True	True	True	Gain-of-function	30341394;26662311;26037647;23182985	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0027-SU_T1.R2	p.G12A	p.G12A	c.G35C	12	25398284	25398284	C	G	G	0.154875717017208	LUAD	True	True	True	Gain-of-function	30341394;26662311;26037647;23182985	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0027-SU_T1.R3	p.G12A	p.G12A	c.G35C	12	25398284	25398284	C	G	G	0.065843621399177	LUAD	True	True	True	Gain-of-function	30341394;26662311;26037647;23182985	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0027-SU_FLN1	p.G12A	p.G12A	c.G35C	12	25398284	25398284	C	G	G	0.14847942754919502	LUAD	True	True	True	Gain-of-function	30341394;26662311;26037647;23182985	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0030-SU_T2.R1	p.G12A	p.G12A	c.G35C	12	25398284	25398284	C	G	G	0.27720207253886	LUAD	True	True	True	Gain-of-function	30341394;26662311;26037647;23182985	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0030-SU_T2.R2	p.G12A	p.G12A	c.G35C	12	25398284	25398284	C	G	G	0.41706161137440795	LUAD	True	True	True	Gain-of-function	30341394;26662311;26037647;23182985	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0030-SU_T2.R3	p.G12A	p.G12A	c.G35C	12	25398284	25398284	C	G	G	0.368932038834951	LUAD	True	True	True	Gain-of-function	30341394;26662311;26037647;23182985	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0032-SU_T1.R1	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.300411522633745	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0032-SU_T1.R2	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.5947786606129399	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0032-SU_T1.R3	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.526448362720403	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0032-SU_T1.R4	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.48270440251572294	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0034-SU_T1.R1	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.240540540540541	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0034-SU_T1.R2	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.323308270676692	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0034-SU_T1.R3	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.31292517006802695	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	EGFR	In_Frame_Del	CRUK0035-BP_T1.R1			c.2237_2237delins-ATTAAGAGAAGCAAC	7	55242467	55242467	A	-ATTAAGAGAAGCAAC	-ATTAAGAGAAGCAAC	0.25271739130434806	LUAD	True	True	True	Likely Gain-of-function	15329413;18000506;15118125;34526717;19536777;18458038;15118073;22019513;23566546;23559152;24457318;22760226;23749122;17192902	Likely Oncogenic	Erlotinib,Osimertinib+Chemotherapy,Erlotinib+Ramucirumab,Afatinib,Gefitinib,Osimertinib,Dacomitinib	Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		22285168;27987585;29151359;37937763;31751012;30659024;23816960;22452895;25589191;20022809;19692680;21670455;22370314;31682542;20573926;29864379;28958502;37879444;37689979;38369013;31661465;34548309;30057690;34084213;38924756;34028784;37710001										
GRCh37	EGFR	In_Frame_Del	CRUK0035-BR_T1.R1			c.2237_2237delins-ATTAAGAGAAGCAAC	7	55242467	55242467	A	-ATTAAGAGAAGCAAC	-ATTAAGAGAAGCAAC	0.13368983957219302	LUAD	True	True	True	Likely Gain-of-function	15329413;18000506;15118125;34526717;19536777;18458038;15118073;22019513;23566546;23559152;24457318;22760226;23749122;17192902	Likely Oncogenic	Erlotinib,Osimertinib+Chemotherapy,Erlotinib+Ramucirumab,Afatinib,Gefitinib,Osimertinib,Dacomitinib	Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		22285168;27987585;29151359;37937763;31751012;30659024;23816960;22452895;25589191;20022809;19692680;21670455;22370314;31682542;20573926;29864379;28958502;37879444;37689979;38369013;31661465;34548309;30057690;34084213;38924756;34028784;37710001										
GRCh37	EGFR	In_Frame_Del	CRUK0035-SU_FLN1			c.2237_2237delins-ATTAAGAGAAGCAAC	7	55242467	55242467	A	-ATTAAGAGAAGCAAC	-ATTAAGAGAAGCAAC	0.19871794871794898	LUAD	True	True	True	Likely Gain-of-function	15329413;18000506;15118125;34526717;19536777;18458038;15118073;22019513;23566546;23559152;24457318;22760226;23749122;17192902	Likely Oncogenic	Erlotinib,Osimertinib+Chemotherapy,Erlotinib+Ramucirumab,Afatinib,Gefitinib,Osimertinib,Dacomitinib	Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		22285168;27987585;29151359;37937763;31751012;30659024;23816960;22452895;25589191;20022809;19692680;21670455;22370314;31682542;20573926;29864379;28958502;37879444;37689979;38369013;31661465;34548309;30057690;34084213;38924756;34028784;37710001										
GRCh37	EGFR	In_Frame_Del	CRUK0035-SU_FLN2			c.2237_2237delins-ATTAAGAGAAGCAAC	7	55242467	55242467	A	-ATTAAGAGAAGCAAC	-ATTAAGAGAAGCAAC	0.125628140703518	LUAD	True	True	True	Likely Gain-of-function	15329413;18000506;15118125;34526717;19536777;18458038;15118073;22019513;23566546;23559152;24457318;22760226;23749122;17192902	Likely Oncogenic	Erlotinib,Osimertinib+Chemotherapy,Erlotinib+Ramucirumab,Afatinib,Gefitinib,Osimertinib,Dacomitinib	Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		22285168;27987585;29151359;37937763;31751012;30659024;23816960;22452895;25589191;20022809;19692680;21670455;22370314;31682542;20573926;29864379;28958502;37879444;37689979;38369013;31661465;34548309;30057690;34084213;38924756;34028784;37710001										
GRCh37	EGFR	In_Frame_Del	CRUK0035-SU_LN01			c.2237_2237delins-ATTAAGAGAAGCAAC	7	55242467	55242467	A	-ATTAAGAGAAGCAAC	-ATTAAGAGAAGCAAC	0.0414201183431953	LUAD	True	True	True	Likely Gain-of-function	15329413;18000506;15118125;34526717;19536777;18458038;15118073;22019513;23566546;23559152;24457318;22760226;23749122;17192902	Likely Oncogenic	Erlotinib,Osimertinib+Chemotherapy,Erlotinib+Ramucirumab,Afatinib,Gefitinib,Osimertinib,Dacomitinib	Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		22285168;27987585;29151359;37937763;31751012;30659024;23816960;22452895;25589191;20022809;19692680;21670455;22370314;31682542;20573926;29864379;28958502;37879444;37689979;38369013;31661465;34548309;30057690;34084213;38924756;34028784;37710001										
GRCh37	EGFR	In_Frame_Del	CRUK0035-SU_T1.R1			c.2237_2237delins-ATTAAGAGAAGCAAC	7	55242467	55242467	A	-ATTAAGAGAAGCAAC	-ATTAAGAGAAGCAAC	0.0683646112600536	LUAD	True	True	True	Likely Gain-of-function	15329413;18000506;15118125;34526717;19536777;18458038;15118073;22019513;23566546;23559152;24457318;22760226;23749122;17192902	Likely Oncogenic	Erlotinib,Osimertinib+Chemotherapy,Erlotinib+Ramucirumab,Afatinib,Gefitinib,Osimertinib,Dacomitinib	Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		22285168;27987585;29151359;37937763;31751012;30659024;23816960;22452895;25589191;20022809;19692680;21670455;22370314;31682542;20573926;29864379;28958502;37879444;37689979;38369013;31661465;34548309;30057690;34084213;38924756;34028784;37710001										
GRCh37	EGFR	In_Frame_Del	CRUK0035-SU_T1.R2			c.2237_2237delins-ATTAAGAGAAGCAAC	7	55242467	55242467	A	-ATTAAGAGAAGCAAC	-ATTAAGAGAAGCAAC	0.0849056603773585	LUAD	True	True	True	Likely Gain-of-function	15329413;18000506;15118125;34526717;19536777;18458038;15118073;22019513;23566546;23559152;24457318;22760226;23749122;17192902	Likely Oncogenic	Erlotinib,Osimertinib+Chemotherapy,Erlotinib+Ramucirumab,Afatinib,Gefitinib,Osimertinib,Dacomitinib	Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		22285168;27987585;29151359;37937763;31751012;30659024;23816960;22452895;25589191;20022809;19692680;21670455;22370314;31682542;20573926;29864379;28958502;37879444;37689979;38369013;31661465;34548309;30057690;34084213;38924756;34028784;37710001										
GRCh37	EGFR	In_Frame_Del	CRUK0035-SU_T1.R3			c.2237_2237delins-ATTAAGAGAAGCAAC	7	55242467	55242467	A	-ATTAAGAGAAGCAAC	-ATTAAGAGAAGCAAC	0.0763274336283186	LUAD	True	True	True	Likely Gain-of-function	15329413;18000506;15118125;34526717;19536777;18458038;15118073;22019513;23566546;23559152;24457318;22760226;23749122;17192902	Likely Oncogenic	Erlotinib,Osimertinib+Chemotherapy,Erlotinib+Ramucirumab,Afatinib,Gefitinib,Osimertinib,Dacomitinib	Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		22285168;27987585;29151359;37937763;31751012;30659024;23816960;22452895;25589191;20022809;19692680;21670455;22370314;31682542;20573926;29864379;28958502;37879444;37689979;38369013;31661465;34548309;30057690;34084213;38924756;34028784;37710001										
GRCh37	EGFR	Missense	CRUK0035-BP_T1.R1	p.T790M	p.T790M	c.C2369T	7	55249071	55249071	C	T	T	0.255482456140351	LUAD	True	True	True	Gain-of-function	15737014;29151359;15728811;34526717;18227510	Oncogenic	Osimertinib					Erlotinib,Gefitinib,Afatinib		LEVEL_R1	LEVEL_1	LEVEL_R1	24478319;26051236;23816963;Yang et al. Abstract# O03.05, IASLC 2013.(http://library.iaslc.org/search-speaker?search_speaker=17991);25923549;30059262;27751847;29151359										
GRCh37	KRAS	Missense	CRUK0036-SU_T1.R1	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.321899736147757	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0036-SU_T1.R2	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.501182033096927	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0036-SU_T1.R3	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.5429447852760739	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0036-SU_T1.R4	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.35549132947976897	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0036-BR_FLN1	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.41075268817204297	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0037-SU_T1.R1	p.Q61L	p.Q61L	c.A182T	12	25380276	25380276	T	A	A	0.33333333333333304	LUAD	True	True	True	Gain-of-function	25437878;28572459;26854029	Oncogenic					Trametinib,Cobimetinib,Binimetinib			LEVEL_4	LEVEL_4		33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0037-SU_T1.R2	p.Q61L	p.Q61L	c.A182T	12	25380276	25380276	T	A	A	0.227665706051873	LUAD	True	True	True	Gain-of-function	25437878;28572459;26854029	Oncogenic					Trametinib,Cobimetinib,Binimetinib			LEVEL_4	LEVEL_4		33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0037-SU_T1.R3	p.Q61L	p.Q61L	c.A182T	12	25380276	25380276	T	A	A	0.25190839694656497	LUAD	True	True	True	Gain-of-function	25437878;28572459;26854029	Oncogenic					Trametinib,Cobimetinib,Binimetinib			LEVEL_4	LEVEL_4		33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0037-SU_T1.R4	p.Q61L	p.Q61L	c.A182T	12	25380276	25380276	T	A	A	0.3497757847533631	LUAD	True	True	True	Gain-of-function	25437878;28572459;26854029	Oncogenic					Trametinib,Cobimetinib,Binimetinib			LEVEL_4	LEVEL_4		33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0037-SU_T1.R5	p.Q61L	p.Q61L	c.A182T	12	25380276	25380276	T	A	A	0.3	LUAD	True	True	True	Gain-of-function	25437878;28572459;26854029	Oncogenic					Trametinib,Cobimetinib,Binimetinib			LEVEL_4	LEVEL_4		33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0038-SU_T1.R1	p.G12D	p.G12D	c.G35A	12	25398284	25398284	C	T	T	0.126182965299685	LUAD	True	True	True	Gain-of-function	17349581;19296721;11751631;15093544;30341394;28572459;20570890;32792368;20147967;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)	Oncogenic			RMC-6236		MRTX-1133,Trametinib,ASP3082,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);36472553;33933896;25435214;24746704;23934108;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)										
GRCh37	KRAS	Missense	CRUK0038-SU_T1.R2	p.G12D	p.G12D	c.G35A	12	25398284	25398284	C	T	T	0.17737003058104	LUAD	True	True	True	Gain-of-function	17349581;19296721;11751631;15093544;30341394;28572459;20570890;32792368;20147967;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)	Oncogenic			RMC-6236		MRTX-1133,Trametinib,ASP3082,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);36472553;33933896;25435214;24746704;23934108;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)										
GRCh37	KRAS	Missense	CRUK0039-SU_T1.R1	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.41025641025640996	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0039-SU_T1.R3	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.35810810810810795	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0040-SU_T1.R1	p.G12D	p.G12D	c.G35A	12	25398284	25398284	C	T	T	0.0673854447439353	LUAD	True	True	True	Gain-of-function	17349581;19296721;11751631;15093544;30341394;28572459;20570890;32792368;20147967;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)	Oncogenic			RMC-6236		MRTX-1133,Trametinib,ASP3082,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);36472553;33933896;25435214;24746704;23934108;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)										
GRCh37	KRAS	Missense	CRUK0040-SU_T1.R2	p.G12D	p.G12D	c.G35A	12	25398284	25398284	C	T	T	0.075	LUAD	True	True	True	Gain-of-function	17349581;19296721;11751631;15093544;30341394;28572459;20570890;32792368;20147967;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)	Oncogenic			RMC-6236		MRTX-1133,Trametinib,ASP3082,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);36472553;33933896;25435214;24746704;23934108;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)										
GRCh37	BRAF	Missense	CRUK0041-SU_T1.R1	p.K601E	p.K601E	c.A1801G	7	140453134	140453134	T	C	C	0.267857142857143	LUAD	True	True	True	Gain-of-function	20179705;26343582;35630083;34590045;28783719;22608338;26643848;31515458;22798288;29320312;28344857;30559419;23248257	Likely Oncogenic				Trametinib	Plixorafenib			LEVEL_3B	LEVEL_3B		28344857;24933606;23248257;22798288;29903896;26466569;28659148;28783719;30559419;Janku et al. Abstract# B176, AACR-NCI-EORTC 2017.(http://mct.aacrjournals.org/content/17/1_Supplement/B176);Fuente et al. Abstract# 3006, J. Clin. Oncol. 2023, Vol 41, Suppl 16.(https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.3006)										
GRCh37	BRAF	Missense	CRUK0041-SU_T1.R2	p.K601E	p.K601E	c.A1801G	7	140453134	140453134	T	C	C	0.18279569892473102	LUAD	True	True	True	Gain-of-function	20179705;26343582;35630083;34590045;28783719;22608338;26643848;31515458;22798288;29320312;28344857;30559419;23248257	Likely Oncogenic				Trametinib	Plixorafenib			LEVEL_3B	LEVEL_3B		28344857;24933606;23248257;22798288;29903896;26466569;28659148;28783719;30559419;Janku et al. Abstract# B176, AACR-NCI-EORTC 2017.(http://mct.aacrjournals.org/content/17/1_Supplement/B176);Fuente et al. Abstract# 3006, J. Clin. Oncol. 2023, Vol 41, Suppl 16.(https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.3006)										
GRCh37	BRAF	Missense	CRUK0041-SU_T1.R3	p.K601E	p.K601E	c.A1801G	7	140453134	140453134	T	C	C	0.283185840707965	LUAD	True	True	True	Gain-of-function	20179705;26343582;35630083;34590045;28783719;22608338;26643848;31515458;22798288;29320312;28344857;30559419;23248257	Likely Oncogenic				Trametinib	Plixorafenib			LEVEL_3B	LEVEL_3B		28344857;24933606;23248257;22798288;29903896;26466569;28659148;28783719;30559419;Janku et al. Abstract# B176, AACR-NCI-EORTC 2017.(http://mct.aacrjournals.org/content/17/1_Supplement/B176);Fuente et al. Abstract# 3006, J. Clin. Oncol. 2023, Vol 41, Suppl 16.(https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.3006)										
GRCh37	BRAF	Missense	CRUK0041-SU_T1.R4	p.K601E	p.K601E	c.A1801G	7	140453134	140453134	T	C	C	0.235668789808917	LUAD	True	True	True	Gain-of-function	20179705;26343582;35630083;34590045;28783719;22608338;26643848;31515458;22798288;29320312;28344857;30559419;23248257	Likely Oncogenic				Trametinib	Plixorafenib			LEVEL_3B	LEVEL_3B		28344857;24933606;23248257;22798288;29903896;26466569;28659148;28783719;30559419;Janku et al. Abstract# B176, AACR-NCI-EORTC 2017.(http://mct.aacrjournals.org/content/17/1_Supplement/B176);Fuente et al. Abstract# 3006, J. Clin. Oncol. 2023, Vol 41, Suppl 16.(https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.3006)										
GRCh37	BRAF	Missense	CRUK0041-BR_T1.R1	p.K601E	p.K601E	c.A1801G	7	140453134	140453134	T	C	C	0.23397435897435895	LUAD	True	True	True	Gain-of-function	20179705;26343582;35630083;34590045;28783719;22608338;26643848;31515458;22798288;29320312;28344857;30559419;23248257	Likely Oncogenic				Trametinib	Plixorafenib			LEVEL_3B	LEVEL_3B		28344857;24933606;23248257;22798288;29903896;26466569;28659148;28783719;30559419;Janku et al. Abstract# B176, AACR-NCI-EORTC 2017.(http://mct.aacrjournals.org/content/17/1_Supplement/B176);Fuente et al. Abstract# 3006, J. Clin. Oncol. 2023, Vol 41, Suppl 16.(https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.3006)										
GRCh37	KRAS	Missense	CRUK0042-SU_T1.R1	p.G12D	p.G12D	c.G35A	12	25398284	25398284	C	T	T	0.11532125205930802	LUAD	True	True	True	Gain-of-function	17349581;19296721;11751631;15093544;30341394;28572459;20570890;32792368;20147967;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)	Oncogenic			RMC-6236		MRTX-1133,Trametinib,ASP3082,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);36472553;33933896;25435214;24746704;23934108;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)										
GRCh37	KRAS	Missense	CRUK0042-SU_T1.R2	p.G12D	p.G12D	c.G35A	12	25398284	25398284	C	T	T	0.0696629213483146	LUAD	True	True	True	Gain-of-function	17349581;19296721;11751631;15093544;30341394;28572459;20570890;32792368;20147967;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)	Oncogenic			RMC-6236		MRTX-1133,Trametinib,ASP3082,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);36472553;33933896;25435214;24746704;23934108;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)										
GRCh37	KRAS	Missense	CRUK0044-SU_T1.R1	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.0559796437659033	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0044-SU_T1.R2	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.03205128205128201	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0044-BR_T1.R1	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.18764845605700697	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	ERBB2	In_Frame_Ins	CRUK0045-SU_T1.R1	p.E770delinsEAYVM	p.E770delinsEAYVM	c.2310_2311insGCATACGTGATG	17	37880981	37880981	-	GCATACGTGATG	GCATACGTGATG	0.128964059196617	LUAD	True	True	False	Gain-of-function	29967253;26559459	Oncogenic	Trastuzumab Deruxtecan	Ado-Trastuzumab Emtansine	Neratinib,Trastuzumab+Pertuzumab+Docetaxel					LEVEL_1	LEVEL_1		34534430;31588020;29989854;30206164;23220880;29420467;15059883;19934333;28959366;35073148										
GRCh37	ERBB2	In_Frame_Ins	CRUK0045-SU_T1.R2	p.E770delinsEAYVM	p.E770delinsEAYVM	c.2310_2311insGCATACGTGATG	17	37880981	37880981	-	GCATACGTGATG	GCATACGTGATG	0.0498812351543943	LUAD	True	True	False	Gain-of-function	29967253;26559459	Oncogenic	Trastuzumab Deruxtecan	Ado-Trastuzumab Emtansine	Neratinib,Trastuzumab+Pertuzumab+Docetaxel					LEVEL_1	LEVEL_1		34534430;31588020;29989854;30206164;23220880;29420467;15059883;19934333;28959366;35073148										
GRCh37	ERBB2	In_Frame_Ins	CRUK0045-SU_T1.R3	p.E770delinsEAYVM	p.E770delinsEAYVM	c.2310_2311insGCATACGTGATG	17	37880981	37880981	-	GCATACGTGATG	GCATACGTGATG	0.0780487804878049	LUAD	True	True	False	Gain-of-function	29967253;26559459	Oncogenic	Trastuzumab Deruxtecan	Ado-Trastuzumab Emtansine	Neratinib,Trastuzumab+Pertuzumab+Docetaxel					LEVEL_1	LEVEL_1		34534430;31588020;29989854;30206164;23220880;29420467;15059883;19934333;28959366;35073148										
GRCh37	KRAS	Missense	CRUK0047-SU_T1.R1	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.0815217391304348	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0047-SU_T1.R2	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.04907975460122701	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0048-SU_T1.R1	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.0372208436724566	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0048-SU_T1.R2	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.0261348005502063	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0048-SU_T1.R3	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.00610500610500611	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	BRAF	Missense	CRUK0048-SU_T1.R1	p.D594N	p.D594N	c.G1780A	7	140453155	140453155	C	T	T	0.157894736842105	LUAD	True	True	True	Gain-of-function	23833300;26498038;36136993;28783719;22798288;28947956	Oncogenic																					
GRCh37	BRAF	Missense	CRUK0048-SU_T1.R2	p.D594N	p.D594N	c.G1780A	7	140453155	140453155	C	T	T	0.285211267605634	LUAD	True	True	True	Gain-of-function	23833300;26498038;36136993;28783719;22798288;28947956	Oncogenic																					
GRCh37	BRAF	Missense	CRUK0048-SU_T1.R3	p.D594N	p.D594N	c.G1780A	7	140453155	140453155	C	T	T	0.30254777070063693	LUAD	True	True	True	Gain-of-function	23833300;26498038;36136993;28783719;22798288;28947956	Oncogenic																					
GRCh37	BRAF	Missense	CRUK0048-BR_T1.R1	p.D594N	p.D594N	c.G1780A	7	140453155	140453155	C	T	T	0.3314285714285711	LUAD	True	True	True	Gain-of-function	23833300;26498038;36136993;28783719;22798288;28947956	Oncogenic																					
GRCh37	BRAF	Missense	CRUK0048-BR_T1.R2	p.D594N	p.D594N	c.G1780A	7	140453155	140453155	C	T	T	0.381720430107527	LUAD	True	True	True	Gain-of-function	23833300;26498038;36136993;28783719;22798288;28947956	Oncogenic																					
GRCh37	KRAS	Missense	CRUK0050-SU_T1.R1	p.G12R	p.G12R	c.G34C	12	25398285	25398285	C	G	G	0.43478260869565205	LUAD	True	True	True	Gain-of-function	30341394;28572459;22722830;32792368	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0050-SU_T1.R2	p.G12R	p.G12R	c.G34C	12	25398285	25398285	C	G	G	0.358490566037736	LUAD	True	True	True	Gain-of-function	30341394;28572459;22722830;32792368	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0050-SU_T1.R3	p.G12R	p.G12R	c.G34C	12	25398285	25398285	C	G	G	0.343478260869565	LUAD	True	True	True	Gain-of-function	30341394;28572459;22722830;32792368	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0050-SU_T1.R4	p.G12R	p.G12R	c.G34C	12	25398285	25398285	C	G	G	0.29642857142857104	LUAD	True	True	True	Gain-of-function	30341394;28572459;22722830;32792368	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0050-SU_T1.R5	p.G12R	p.G12R	c.G34C	12	25398285	25398285	C	G	G	0.18018018018018	LUAD	True	True	True	Gain-of-function	30341394;28572459;22722830;32792368	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0051-SU_T1.R2	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.313218390804598	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0051-SU_T1.R3	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.37250554323725105	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0051-SU_T1.R4	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.19720496894409897	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0052-SU_T1.R1	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.366247755834829	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0052-SU_T1.R2	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.0675675675675676	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0052-SU_T1.R3	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.24508050089445396	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0052-SU_T1.R4	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.164345403899721	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0052-SU_FLN1	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.23636363636363603	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	EGFR	Missense	CRUK0054-SU_T1.R1	p.L858R	p.L858R	c.T2573G	7	55259515	55259515	T	G	G	0.23886639676113397	LUAD	True	True	True	Gain-of-function	15329413;15118073;15118125;34526717	Oncogenic	Erlotinib,Osimertinib+Chemotherapy,Erlotinib+Ramucirumab,Afatinib,Gefitinib,Osimertinib,Dacomitinib	Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		22285168;27987585;29151359;37937763;31751012;30659024;23816960;22452895;25589191;20022809;19692680;21670455;22370314;31682542;20573926;29864379;28958502;37879444;37689979;38369013;31661465;34548309;30057690;34084213;38924756;34028784;37710001										
GRCh37	EGFR	Missense	CRUK0054-SU_T1.R2	p.L858R	p.L858R	c.T2573G	7	55259515	55259515	T	G	G	0.299319727891156	LUAD	True	True	True	Gain-of-function	15329413;15118073;15118125;34526717	Oncogenic	Erlotinib,Osimertinib+Chemotherapy,Erlotinib+Ramucirumab,Afatinib,Gefitinib,Osimertinib,Dacomitinib	Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		22285168;27987585;29151359;37937763;31751012;30659024;23816960;22452895;25589191;20022809;19692680;21670455;22370314;31682542;20573926;29864379;28958502;37879444;37689979;38369013;31661465;34548309;30057690;34084213;38924756;34028784;37710001										
GRCh37	KRAS	Missense	CRUK0057-SU_T1.R1	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.25063938618925796	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0057-SU_T1.R2	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.36389280677009905	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	EGFR	Missense	CRUK0058-SU_T1.R1	p.L861Q	p.L861Q	c.T2582A	7	55259524	55259524	T	A	A	0.3582474226804121	LUAD	True	True	True	Gain-of-function	21531810;18508816;29141884;16467085;17177598;25668120;31825714;21841502;15897572;34526717;21252719;19536777;18325048;19147750;26051236;18676761;23912954;24457318;22760226;20808254;23749122;24285021	Oncogenic	Afatinib	Dacomitinib,Erlotinib,Osimertinib,Gefitinib,Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		26051236;22452895;25589191;28336552;23816960;35770100;25668120;37991747;31825714;37879444;37689979;38369013;31661465;34548309;30057690;34084213;Cho et al. Abstract #8516, ASCO 2024.(https://ascopubs.org/doi/pdf/10.1200/JCO.2024.42.16_suppl.8516)										
GRCh37	EGFR	Missense	CRUK0058-SU_T1.R2	p.L861Q	p.L861Q	c.T2582A	7	55259524	55259524	T	A	A	0.370288248337029	LUAD	True	True	True	Gain-of-function	21531810;18508816;29141884;16467085;17177598;25668120;31825714;21841502;15897572;34526717;21252719;19536777;18325048;19147750;26051236;18676761;23912954;24457318;22760226;20808254;23749122;24285021	Oncogenic	Afatinib	Dacomitinib,Erlotinib,Osimertinib,Gefitinib,Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		26051236;22452895;25589191;28336552;23816960;35770100;25668120;37991747;31825714;37879444;37689979;38369013;31661465;34548309;30057690;34084213;Cho et al. Abstract #8516, ASCO 2024.(https://ascopubs.org/doi/pdf/10.1200/JCO.2024.42.16_suppl.8516)										
GRCh37	KRAS	Missense	CRUK0059-SU_T1.R1	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.130434782608696	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0059-SU_T1.R2	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.168604651162791	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0115-SU_T1.R1	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.0975056689342404	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0115-SU_T1.R2	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.420689655172414	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0115-SU_T1.R3	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.103671706263499	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0115-SU_T1.R4	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.512022630834512	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	EGFR	In_Frame_Del	CRUK0124-SU_T1.R1			c.2234_2234delins-GGAATTAAGAGAAGC	7	55242464	55242464	A	-GGAATTAAGAGAAGC	-GGAATTAAGAGAAGC	0.16	LUAD	True	True	True	Likely Gain-of-function	15329413;18000506;15118125;34526717;19536777;18458038;15118073;22019513;23566546;23559152;24457318;22760226;23749122;17192902	Likely Oncogenic	Erlotinib,Osimertinib+Chemotherapy,Erlotinib+Ramucirumab,Afatinib,Gefitinib,Osimertinib,Dacomitinib	Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		22285168;27987585;29151359;37937763;31751012;30659024;23816960;22452895;25589191;20022809;19692680;21670455;22370314;31682542;20573926;29864379;28958502;37879444;37689979;38369013;31661465;34548309;30057690;34084213;38924756;34028784;37710001										
GRCh37	EGFR	In_Frame_Del	CRUK0124-SU_T1.R2			c.2234_2234delins-GGAATTAAGAGAAGC	7	55242464	55242464	A	-GGAATTAAGAGAAGC	-GGAATTAAGAGAAGC	0.148773006134969	LUAD	True	True	True	Likely Gain-of-function	15329413;18000506;15118125;34526717;19536777;18458038;15118073;22019513;23566546;23559152;24457318;22760226;23749122;17192902	Likely Oncogenic	Erlotinib,Osimertinib+Chemotherapy,Erlotinib+Ramucirumab,Afatinib,Gefitinib,Osimertinib,Dacomitinib	Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		22285168;27987585;29151359;37937763;31751012;30659024;23816960;22452895;25589191;20022809;19692680;21670455;22370314;31682542;20573926;29864379;28958502;37879444;37689979;38369013;31661465;34548309;30057690;34084213;38924756;34028784;37710001										
GRCh37	KRAS	Missense	CRUK0128-SU_T1.R1	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.0639032815198618	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0128-SU_T1.R2	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.0431893687707641	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	BRAF	Missense	CRUK0157-SU_T1.R1	p.G469A	p.G469A	c.G1406C	7	140481402	140481402	C	G	G	0.133451957295374	LUAD	True	True	True	Gain-of-function	20179705;26343582;12068308;29247021;28783719;22510884;22773810;16439621;31924734;23833300;31515458;29320312;32540409	Oncogenic					Plixorafenib			LEVEL_4	LEVEL_4		26466569;28659148;28783719;30559419;Janku et al. Abstract# B176, AACR-NCI-EORTC 2017.(http://mct.aacrjournals.org/content/17/1_Supplement/B176);Fuente et al. Abstract# 3006, J. Clin. Oncol. 2023, Vol 41, Suppl 16.(https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.3006)										
GRCh37	BRAF	Missense	CRUK0157-SU_T1.R2	p.G469A	p.G469A	c.G1406C	7	140481402	140481402	C	G	G	0.20577617328519895	LUAD	True	True	True	Gain-of-function	20179705;26343582;12068308;29247021;28783719;22510884;22773810;16439621;31924734;23833300;31515458;29320312;32540409	Oncogenic					Plixorafenib			LEVEL_4	LEVEL_4		26466569;28659148;28783719;30559419;Janku et al. Abstract# B176, AACR-NCI-EORTC 2017.(http://mct.aacrjournals.org/content/17/1_Supplement/B176);Fuente et al. Abstract# 3006, J. Clin. Oncol. 2023, Vol 41, Suppl 16.(https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.3006)										
GRCh37	BRAF	Missense	CRUK0157-SU_T1.R3	p.G469A	p.G469A	c.G1406C	7	140481402	140481402	C	G	G	0.21970920840064603	LUAD	True	True	True	Gain-of-function	20179705;26343582;12068308;29247021;28783719;22510884;22773810;16439621;31924734;23833300;31515458;29320312;32540409	Oncogenic					Plixorafenib			LEVEL_4	LEVEL_4		26466569;28659148;28783719;30559419;Janku et al. Abstract# B176, AACR-NCI-EORTC 2017.(http://mct.aacrjournals.org/content/17/1_Supplement/B176);Fuente et al. Abstract# 3006, J. Clin. Oncol. 2023, Vol 41, Suppl 16.(https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.3006)										
GRCh37	BRAF	Missense	CRUK0157-SU_T1.R4	p.G469A	p.G469A	c.G1406C	7	140481402	140481402	C	G	G	0.27666151468315303	LUAD	True	True	True	Gain-of-function	20179705;26343582;12068308;29247021;28783719;22510884;22773810;16439621;31924734;23833300;31515458;29320312;32540409	Oncogenic					Plixorafenib			LEVEL_4	LEVEL_4		26466569;28659148;28783719;30559419;Janku et al. Abstract# B176, AACR-NCI-EORTC 2017.(http://mct.aacrjournals.org/content/17/1_Supplement/B176);Fuente et al. Abstract# 3006, J. Clin. Oncol. 2023, Vol 41, Suppl 16.(https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.3006)										
GRCh37	BRAF	Missense	CRUK0157-SU_T1.R5	p.G469A	p.G469A	c.G1406C	7	140481402	140481402	C	G	G	0.22580645161290303	LUAD	True	True	True	Gain-of-function	20179705;26343582;12068308;29247021;28783719;22510884;22773810;16439621;31924734;23833300;31515458;29320312;32540409	Oncogenic					Plixorafenib			LEVEL_4	LEVEL_4		26466569;28659148;28783719;30559419;Janku et al. Abstract# B176, AACR-NCI-EORTC 2017.(http://mct.aacrjournals.org/content/17/1_Supplement/B176);Fuente et al. Abstract# 3006, J. Clin. Oncol. 2023, Vol 41, Suppl 16.(https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.3006)										
GRCh37	BRAF	Missense	CRUK0157-SU_T1.R6	p.G469A	p.G469A	c.G1406C	7	140481402	140481402	C	G	G	0.23973727422003302	LUAD	True	True	True	Gain-of-function	20179705;26343582;12068308;29247021;28783719;22510884;22773810;16439621;31924734;23833300;31515458;29320312;32540409	Oncogenic					Plixorafenib			LEVEL_4	LEVEL_4		26466569;28659148;28783719;30559419;Janku et al. Abstract# B176, AACR-NCI-EORTC 2017.(http://mct.aacrjournals.org/content/17/1_Supplement/B176);Fuente et al. Abstract# 3006, J. Clin. Oncol. 2023, Vol 41, Suppl 16.(https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.3006)										
GRCh37	BRAF	Missense	CRUK0157-SU_T1.R7	p.G469A	p.G469A	c.G1406C	7	140481402	140481402	C	G	G	0.28741496598639504	LUAD	True	True	True	Gain-of-function	20179705;26343582;12068308;29247021;28783719;22510884;22773810;16439621;31924734;23833300;31515458;29320312;32540409	Oncogenic					Plixorafenib			LEVEL_4	LEVEL_4		26466569;28659148;28783719;30559419;Janku et al. Abstract# B176, AACR-NCI-EORTC 2017.(http://mct.aacrjournals.org/content/17/1_Supplement/B176);Fuente et al. Abstract# 3006, J. Clin. Oncol. 2023, Vol 41, Suppl 16.(https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.3006)										
GRCh37	BRAF	Missense	CRUK0157-SU_T1.R8	p.G469A	p.G469A	c.G1406C	7	140481402	140481402	C	G	G	0.17647058823529396	LUAD	True	True	True	Gain-of-function	20179705;26343582;12068308;29247021;28783719;22510884;22773810;16439621;31924734;23833300;31515458;29320312;32540409	Oncogenic					Plixorafenib			LEVEL_4	LEVEL_4		26466569;28659148;28783719;30559419;Janku et al. Abstract# B176, AACR-NCI-EORTC 2017.(http://mct.aacrjournals.org/content/17/1_Supplement/B176);Fuente et al. Abstract# 3006, J. Clin. Oncol. 2023, Vol 41, Suppl 16.(https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.3006)										
GRCh37	KRAS	Missense	CRUK0159-SU_T1.R1	p.G12S	p.G12S	c.G34A	12	25398285	25398285	C	T	T	0.348837209302326	LUAD	True	True	True	Gain-of-function	28572459;25284075;26184075	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0159-SU_T1.R2	p.G12S	p.G12S	c.G34A	12	25398285	25398285	C	T	T	0.23511904761904803	LUAD	True	True	True	Gain-of-function	28572459;25284075;26184075	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0159-SU_T1.R3	p.G12S	p.G12S	c.G34A	12	25398285	25398285	C	T	T	0.46153846153846206	LUAD	True	True	True	Gain-of-function	28572459;25284075;26184075	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0182-SU_T1.R1	p.G12D	p.G12D	c.G35A	12	25398284	25398284	C	T	T	0.0368763557483731	LUAD	True	True	True	Gain-of-function	17349581;19296721;11751631;15093544;30341394;28572459;20570890;32792368;20147967;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)	Oncogenic			RMC-6236		MRTX-1133,Trametinib,ASP3082,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);36472553;33933896;25435214;24746704;23934108;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)										
GRCh37	KRAS	Missense	CRUK0182-SU_T1.R2	p.G12D	p.G12D	c.G35A	12	25398284	25398284	C	T	T	0.0393258426966292	LUAD	True	True	True	Gain-of-function	17349581;19296721;11751631;15093544;30341394;28572459;20570890;32792368;20147967;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)	Oncogenic			RMC-6236		MRTX-1133,Trametinib,ASP3082,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);36472553;33933896;25435214;24746704;23934108;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)										
GRCh37	KRAS	Missense	CRUK0206-SU_T1.R1	p.Q61L	p.Q61L	c.A182T	12	25380276	25380276	T	A	A	0.29441624365482205	LUAD	True	True	True	Gain-of-function	25437878;28572459;26854029	Oncogenic					Trametinib,Cobimetinib,Binimetinib			LEVEL_4	LEVEL_4		33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0206-SU_T1.R2	p.Q61L	p.Q61L	c.A182T	12	25380276	25380276	T	A	A	0.485436893203884	LUAD	True	True	True	Gain-of-function	25437878;28572459;26854029	Oncogenic					Trametinib,Cobimetinib,Binimetinib			LEVEL_4	LEVEL_4		33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0206-SU_T1.R3	p.Q61L	p.Q61L	c.A182T	12	25380276	25380276	T	A	A	0.26170212765957396	LUAD	True	True	True	Gain-of-function	25437878;28572459;26854029	Oncogenic					Trametinib,Cobimetinib,Binimetinib			LEVEL_4	LEVEL_4		33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0206-SU_T1.R4	p.Q61L	p.Q61L	c.A182T	12	25380276	25380276	T	A	A	0.45070422535211296	LUAD	True	True	True	Gain-of-function	25437878;28572459;26854029	Oncogenic					Trametinib,Cobimetinib,Binimetinib			LEVEL_4	LEVEL_4		33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0206-SU_T1.R5	p.Q61L	p.Q61L	c.A182T	12	25380276	25380276	T	A	A	0.32549019607843105	LUAD	True	True	True	Gain-of-function	25437878;28572459;26854029	Oncogenic					Trametinib,Cobimetinib,Binimetinib			LEVEL_4	LEVEL_4		33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0206-MR_T1.R1	p.Q61L	p.Q61L	c.A182T	12	25380276	25380276	T	A	A	0.47484276729559705	LUAD	True	True	True	Gain-of-function	25437878;28572459;26854029	Oncogenic					Trametinib,Cobimetinib,Binimetinib			LEVEL_4	LEVEL_4		33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0206-MR_T1.R2	p.Q61L	p.Q61L	c.A182T	12	25380276	25380276	T	A	A	0.27173913043478304	LUAD	True	True	True	Gain-of-function	25437878;28572459;26854029	Oncogenic					Trametinib,Cobimetinib,Binimetinib			LEVEL_4	LEVEL_4		33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0206-MR_T1.R3	p.Q61L	p.Q61L	c.A182T	12	25380276	25380276	T	A	A	0.5366666666666671	LUAD	True	True	True	Gain-of-function	25437878;28572459;26854029	Oncogenic					Trametinib,Cobimetinib,Binimetinib			LEVEL_4	LEVEL_4		33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0206-MR_T1.R4	p.Q61L	p.Q61L	c.A182T	12	25380276	25380276	T	A	A	0.266106442577031	LUAD	True	True	True	Gain-of-function	25437878;28572459;26854029	Oncogenic					Trametinib,Cobimetinib,Binimetinib			LEVEL_4	LEVEL_4		33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0206-MR_T1.R5	p.Q61L	p.Q61L	c.A182T	12	25380276	25380276	T	A	A	0.419540229885057	LUAD	True	True	True	Gain-of-function	25437878;28572459;26854029	Oncogenic					Trametinib,Cobimetinib,Binimetinib			LEVEL_4	LEVEL_4		33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0206-SU_FLN1	p.Q61L	p.Q61L	c.A182T	12	25380276	25380276	T	A	A	0.3928571428571429	LUAD	True	True	True	Gain-of-function	25437878;28572459;26854029	Oncogenic					Trametinib,Cobimetinib,Binimetinib			LEVEL_4	LEVEL_4		33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0212-SU_T1.R1	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.31047619047619	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0212-SU_T1.R2	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.13211845102505698	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0223-SU_T1.R1	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.152284263959391	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0223-SU_T1.R2	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.205014749262537	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0233-SU_T1.R1	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.219718309859155	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0233-SU_T1.R2	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.22711267605633803	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0247-SU_T1.R1	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.0715990453460621	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0247-SU_T1.R2	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.13107822410148	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0259-SU_T1.R1	p.G12S	p.G12S	c.G34A	12	25398285	25398285	C	T	T	0.236979166666667	LUAD	True	True	True	Gain-of-function	28572459;25284075;26184075	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0259-SU_T1.R2	p.G12S	p.G12S	c.G34A	12	25398285	25398285	C	T	T	0.119241192411924	LUAD	True	True	True	Gain-of-function	28572459;25284075;26184075	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	EGFR	Missense	CRUK0267-SU_T1.R1	p.L861Q	p.L861Q	c.T2582A	7	55259524	55259524	T	A	A	0.23675496688741698	LUAD	True	True	True	Gain-of-function	21531810;18508816;29141884;16467085;17177598;25668120;31825714;21841502;15897572;34526717;21252719;19536777;18325048;19147750;26051236;18676761;23912954;24457318;22760226;20808254;23749122;24285021	Oncogenic	Afatinib	Dacomitinib,Erlotinib,Osimertinib,Gefitinib,Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		26051236;22452895;25589191;28336552;23816960;35770100;25668120;37991747;31825714;37879444;37689979;38369013;31661465;34548309;30057690;34084213;Cho et al. Abstract #8516, ASCO 2024.(https://ascopubs.org/doi/pdf/10.1200/JCO.2024.42.16_suppl.8516)										
GRCh37	EGFR	Missense	CRUK0267-SU_T1.R2	p.L861Q	p.L861Q	c.T2582A	7	55259524	55259524	T	A	A	0.4808510638297871	LUAD	True	True	True	Gain-of-function	21531810;18508816;29141884;16467085;17177598;25668120;31825714;21841502;15897572;34526717;21252719;19536777;18325048;19147750;26051236;18676761;23912954;24457318;22760226;20808254;23749122;24285021	Oncogenic	Afatinib	Dacomitinib,Erlotinib,Osimertinib,Gefitinib,Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		26051236;22452895;25589191;28336552;23816960;35770100;25668120;37991747;31825714;37879444;37689979;38369013;31661465;34548309;30057690;34084213;Cho et al. Abstract #8516, ASCO 2024.(https://ascopubs.org/doi/pdf/10.1200/JCO.2024.42.16_suppl.8516)										
GRCh37	BRAF	Missense	CRUK0272-SU_T1.R1	p.D594N	p.D594N	c.G1780A	7	140453155	140453155	C	T	T	0.53030303030303	LUAD	True	True	True	Gain-of-function	23833300;26498038;36136993;28783719;22798288;28947956	Oncogenic																					
GRCh37	BRAF	Missense	CRUK0272-SU_T1.R2	p.D594N	p.D594N	c.G1780A	7	140453155	140453155	C	T	T	0.267942583732057	LUAD	True	True	True	Gain-of-function	23833300;26498038;36136993;28783719;22798288;28947956	Oncogenic																					
GRCh37	BRAF	Missense	CRUK0272-SU_T1.R3	p.D594N	p.D594N	c.G1780A	7	140453155	140453155	C	T	T	0.43598615916955	LUAD	True	True	True	Gain-of-function	23833300;26498038;36136993;28783719;22798288;28947956	Oncogenic																					
GRCh37	BRAF	Missense	CRUK0272-SU_T1.R4	p.D594N	p.D594N	c.G1780A	7	140453155	140453155	C	T	T	0.185	LUAD	True	True	True	Gain-of-function	23833300;26498038;36136993;28783719;22798288;28947956	Oncogenic																					
GRCh37	BRAF	Missense	CRUK0272-SU_T1.R5	p.D594N	p.D594N	c.G1780A	7	140453155	140453155	C	T	T	0.114864864864865	LUAD	True	True	True	Gain-of-function	23833300;26498038;36136993;28783719;22798288;28947956	Oncogenic																					
GRCh37	KRAS	Missense	CRUK0274-SU_T1.R1	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.32388663967611303	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0274-SU_T1.R2	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.35057471264367795	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0274-SU_T1.R3	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.28431372549019607	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0274-SU_T1.R4	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.25625	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0276-SU_T1.R1	p.G12A	p.G12A	c.G35C	12	25398284	25398284	C	G	G	0.45539033457249106	LUAD	True	True	True	Gain-of-function	30341394;26662311;26037647;23182985	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0276-SU_T1.R2	p.G12A	p.G12A	c.G35C	12	25398284	25398284	C	G	G	0.458448753462604	LUAD	True	True	True	Gain-of-function	30341394;26662311;26037647;23182985	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0276-SU_T1.R3	p.G12A	p.G12A	c.G35C	12	25398284	25398284	C	G	G	0.43899018232819104	LUAD	True	True	True	Gain-of-function	30341394;26662311;26037647;23182985	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0280-SU_T1.R1	p.G12D	p.G12D	c.G35A	12	25398284	25398284	C	T	T	0.338709677419355	LUAD	True	True	True	Gain-of-function	17349581;19296721;11751631;15093544;30341394;28572459;20570890;32792368;20147967;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)	Oncogenic			RMC-6236		MRTX-1133,Trametinib,ASP3082,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);36472553;33933896;25435214;24746704;23934108;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)										
GRCh37	KRAS	Missense	CRUK0280-SU_T1.R2	p.G12D	p.G12D	c.G35A	12	25398284	25398284	C	T	T	0.414519906323185	LUAD	True	True	True	Gain-of-function	17349581;19296721;11751631;15093544;30341394;28572459;20570890;32792368;20147967;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)	Oncogenic			RMC-6236		MRTX-1133,Trametinib,ASP3082,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);36472553;33933896;25435214;24746704;23934108;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)										
GRCh37	KRAS	Missense	CRUK0280-SU_T1.R3	p.G12D	p.G12D	c.G35A	12	25398284	25398284	C	T	T	0.193717277486911	LUAD	True	True	True	Gain-of-function	17349581;19296721;11751631;15093544;30341394;28572459;20570890;32792368;20147967;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)	Oncogenic			RMC-6236		MRTX-1133,Trametinib,ASP3082,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);36472553;33933896;25435214;24746704;23934108;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)										
GRCh37	KRAS	Missense	CRUK0280-SU_T1.R4	p.G12D	p.G12D	c.G35A	12	25398284	25398284	C	T	T	0.0653061224489796	LUAD	True	True	True	Gain-of-function	17349581;19296721;11751631;15093544;30341394;28572459;20570890;32792368;20147967;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)	Oncogenic			RMC-6236		MRTX-1133,Trametinib,ASP3082,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);36472553;33933896;25435214;24746704;23934108;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)										
GRCh37	KRAS	Missense	CRUK0280-SU_T1.R5	p.G12D	p.G12D	c.G35A	12	25398284	25398284	C	T	T	0.39964788732394396	LUAD	True	True	True	Gain-of-function	17349581;19296721;11751631;15093544;30341394;28572459;20570890;32792368;20147967;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)	Oncogenic			RMC-6236		MRTX-1133,Trametinib,ASP3082,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);36472553;33933896;25435214;24746704;23934108;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)										
GRCh37	KRAS	Missense	CRUK0284-SU_T1.R1	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.23444976076555	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0284-SU_T1.R2	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.20564516129032298	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0284-SU_T1.R3	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.20792079207920802	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0284-SU_T1.R4	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.16608391608391598	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0284-SU_T1.R5	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.273913043478261	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0284-BP_T1.R1	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.14012738853503198	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0284-BR_T1.R1	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.182741116751269	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0287-SU_T1.R1	p.G13C	p.G13C	c.G37T	12	25398282	25398282	C	A	A	0.606498194945848	LUAD	True	True	True	Gain-of-function	28572459;21079152;25705018	Oncogenic					Trametinib,Cobimetinib,Binimetinib			LEVEL_4	LEVEL_4		33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0287-SU_T1.R2	p.G13C	p.G13C	c.G37T	12	25398282	25398282	C	A	A	0.652517275419546	LUAD	True	True	True	Gain-of-function	28572459;21079152;25705018	Oncogenic					Trametinib,Cobimetinib,Binimetinib			LEVEL_4	LEVEL_4		33933896;25435214;24746704;23934108										
GRCh37	EGFR	Missense	CRUK0297-SU_T1.R1	p.L858R	p.L858R	c.T2573G	7	55259515	55259515	T	G	G	0.316412859560068	LUAD	True	True	True	Gain-of-function	15329413;15118073;15118125;34526717	Oncogenic	Erlotinib,Osimertinib+Chemotherapy,Erlotinib+Ramucirumab,Afatinib,Gefitinib,Osimertinib,Dacomitinib	Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		22285168;27987585;29151359;37937763;31751012;30659024;23816960;22452895;25589191;20022809;19692680;21670455;22370314;31682542;20573926;29864379;28958502;37879444;37689979;38369013;31661465;34548309;30057690;34084213;38924756;34028784;37710001										
GRCh37	EGFR	Missense	CRUK0297-SU_T1.R2	p.L858R	p.L858R	c.T2573G	7	55259515	55259515	T	G	G	0.316639741518578	LUAD	True	True	True	Gain-of-function	15329413;15118073;15118125;34526717	Oncogenic	Erlotinib,Osimertinib+Chemotherapy,Erlotinib+Ramucirumab,Afatinib,Gefitinib,Osimertinib,Dacomitinib	Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		22285168;27987585;29151359;37937763;31751012;30659024;23816960;22452895;25589191;20022809;19692680;21670455;22370314;31682542;20573926;29864379;28958502;37879444;37689979;38369013;31661465;34548309;30057690;34084213;38924756;34028784;37710001										
GRCh37	EGFR	Missense	CRUK0297-SU_T1.R3	p.L858R	p.L858R	c.T2573G	7	55259515	55259515	T	G	G	0.414312617702448	LUAD	True	True	True	Gain-of-function	15329413;15118073;15118125;34526717	Oncogenic	Erlotinib,Osimertinib+Chemotherapy,Erlotinib+Ramucirumab,Afatinib,Gefitinib,Osimertinib,Dacomitinib	Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		22285168;27987585;29151359;37937763;31751012;30659024;23816960;22452895;25589191;20022809;19692680;21670455;22370314;31682542;20573926;29864379;28958502;37879444;37689979;38369013;31661465;34548309;30057690;34084213;38924756;34028784;37710001										
GRCh37	EGFR	Missense	CRUK0297-SU_T1.R4	p.L858R	p.L858R	c.T2573G	7	55259515	55259515	T	G	G	0.326810176125245	LUAD	True	True	True	Gain-of-function	15329413;15118073;15118125;34526717	Oncogenic	Erlotinib,Osimertinib+Chemotherapy,Erlotinib+Ramucirumab,Afatinib,Gefitinib,Osimertinib,Dacomitinib	Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		22285168;27987585;29151359;37937763;31751012;30659024;23816960;22452895;25589191;20022809;19692680;21670455;22370314;31682542;20573926;29864379;28958502;37879444;37689979;38369013;31661465;34548309;30057690;34084213;38924756;34028784;37710001										
GRCh37	EGFR	Missense	CRUK0297-SU_T1.R5	p.L858R	p.L858R	c.T2573G	7	55259515	55259515	T	G	G	0.612307692307692	LUAD	True	True	True	Gain-of-function	15329413;15118073;15118125;34526717	Oncogenic	Erlotinib,Osimertinib+Chemotherapy,Erlotinib+Ramucirumab,Afatinib,Gefitinib,Osimertinib,Dacomitinib	Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		22285168;27987585;29151359;37937763;31751012;30659024;23816960;22452895;25589191;20022809;19692680;21670455;22370314;31682542;20573926;29864379;28958502;37879444;37689979;38369013;31661465;34548309;30057690;34084213;38924756;34028784;37710001										
GRCh37	EGFR	Missense	CRUK0299-SU_T1.R1	p.G719C	p.G719C	c.G2155T	7	55241707	55241707	G	T	T	0.450847457627119	LUAD	True	True	True	Likely Gain-of-function	21531810;29141884;15118073;18261621;31825714;31931137;21841502;Chen et al. JCO Precision Oncology 2024 Vol 8, Number 8.(https://ascopubs.org/doi/10.1200/PO.23.00454)	Oncogenic	Afatinib	Amivantamab+Chemotherapy,Dacomitinib,Osimertinib,Erlotinib,Gefitinib	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		23816960;22452895;25589191;37879444;35770100;37991747;31825714;25668120;37689979;38369013;31661465;34548309;30057690;34084213;Cho et al. Abstract #8516, ASCO 2024.(https://ascopubs.org/doi/pdf/10.1200/JCO.2024.42.16_suppl.8516)										
GRCh37	EGFR	Missense	CRUK0299-SU_T1.R2	p.G719C	p.G719C	c.G2155T	7	55241707	55241707	G	T	T	0.435684647302905	LUAD	True	True	True	Likely Gain-of-function	21531810;29141884;15118073;18261621;31825714;31931137;21841502;Chen et al. JCO Precision Oncology 2024 Vol 8, Number 8.(https://ascopubs.org/doi/10.1200/PO.23.00454)	Oncogenic	Afatinib	Amivantamab+Chemotherapy,Dacomitinib,Osimertinib,Erlotinib,Gefitinib	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		23816960;22452895;25589191;37879444;35770100;37991747;31825714;25668120;37689979;38369013;31661465;34548309;30057690;34084213;Cho et al. Abstract #8516, ASCO 2024.(https://ascopubs.org/doi/pdf/10.1200/JCO.2024.42.16_suppl.8516)										
GRCh37	EGFR	Missense	CRUK0299-BR_FLN1	p.G719C	p.G719C	c.G2155T	7	55241707	55241707	G	T	T	0.269230769230769	LUAD	True	True	True	Likely Gain-of-function	21531810;29141884;15118073;18261621;31825714;31931137;21841502;Chen et al. JCO Precision Oncology 2024 Vol 8, Number 8.(https://ascopubs.org/doi/10.1200/PO.23.00454)	Oncogenic	Afatinib	Amivantamab+Chemotherapy,Dacomitinib,Osimertinib,Erlotinib,Gefitinib	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		23816960;22452895;25589191;37879444;35770100;37991747;31825714;25668120;37689979;38369013;31661465;34548309;30057690;34084213;Cho et al. Abstract #8516, ASCO 2024.(https://ascopubs.org/doi/pdf/10.1200/JCO.2024.42.16_suppl.8516)										
GRCh37	EGFR	Missense	CRUK0299-BR_FLN2	p.G719C	p.G719C	c.G2155T	7	55241707	55241707	G	T	T	0.22569444444444395	LUAD	True	True	True	Likely Gain-of-function	21531810;29141884;15118073;18261621;31825714;31931137;21841502;Chen et al. JCO Precision Oncology 2024 Vol 8, Number 8.(https://ascopubs.org/doi/10.1200/PO.23.00454)	Oncogenic	Afatinib	Amivantamab+Chemotherapy,Dacomitinib,Osimertinib,Erlotinib,Gefitinib	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		23816960;22452895;25589191;37879444;35770100;37991747;31825714;25668120;37689979;38369013;31661465;34548309;30057690;34084213;Cho et al. Abstract #8516, ASCO 2024.(https://ascopubs.org/doi/pdf/10.1200/JCO.2024.42.16_suppl.8516)										
GRCh37	EGFR	Missense	CRUK0299-SU_FLN1	p.G719C	p.G719C	c.G2155T	7	55241707	55241707	G	T	T	0.22891566265060198	LUAD	True	True	True	Likely Gain-of-function	21531810;29141884;15118073;18261621;31825714;31931137;21841502;Chen et al. JCO Precision Oncology 2024 Vol 8, Number 8.(https://ascopubs.org/doi/10.1200/PO.23.00454)	Oncogenic	Afatinib	Amivantamab+Chemotherapy,Dacomitinib,Osimertinib,Erlotinib,Gefitinib	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		23816960;22452895;25589191;37879444;35770100;37991747;31825714;25668120;37689979;38369013;31661465;34548309;30057690;34084213;Cho et al. Abstract #8516, ASCO 2024.(https://ascopubs.org/doi/pdf/10.1200/JCO.2024.42.16_suppl.8516)										
GRCh37	KRAS	Missense	CRUK0301-SU_FLN1	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.116412213740458	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0301-SU_T1.R1	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.0742268041237113	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0301-SU_T1.R2	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.0481012658227848	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	BRAF	Missense	CRUK0305-SU_T1.R2	p.G466A	p.G466A	c.G1397C	7	140481411	140481411	C	G	G	0.0882708585247884	LUAD	True	True	True	Gain-of-function	31924734;31959346;12068308;28783719;33669326;15035987;28481359;Wolf et al. Abstract# 1387p, Annals of Oncology 2020.(https://www.annalsofoncology.org/article/S0923-7534%2820%2941697-7/fulltext)	Oncogenic																					
GRCh37	BRAF	Missense	CRUK0305-SU_T1.R3	p.G466A	p.G466A	c.G1397C	7	140481411	140481411	C	G	G	0.236728837876614	LUAD	True	True	True	Gain-of-function	31924734;31959346;12068308;28783719;33669326;15035987;28481359;Wolf et al. Abstract# 1387p, Annals of Oncology 2020.(https://www.annalsofoncology.org/article/S0923-7534%2820%2941697-7/fulltext)	Oncogenic																					
GRCh37	KRAS	Missense	CRUK0313-SU_T1.R1	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.156199677938808	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0313-SU_T1.R2	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.23349056603773602	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	BRAF	Missense	CRUK0313-SU_T1.R2	p.G466A	p.G466A	c.G1397C	7	140481411	140481411	C	G	G	0.0963172804532578	LUAD	True	True	True	Gain-of-function	31924734;31959346;12068308;28783719;33669326;15035987;28481359;Wolf et al. Abstract# 1387p, Annals of Oncology 2020.(https://www.annalsofoncology.org/article/S0923-7534%2820%2941697-7/fulltext)	Oncogenic																					
GRCh37	KRAS	Missense	CRUK0314-SU_T1.R1	p.G12A	p.G12A	c.G35C	12	25398284	25398284	C	G	G	0.192660550458716	LUAD	True	True	True	Gain-of-function	30341394;26662311;26037647;23182985	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0314-SU_T1.R2	p.G12A	p.G12A	c.G35C	12	25398284	25398284	C	G	G	0.177350427350427	LUAD	True	True	True	Gain-of-function	30341394;26662311;26037647;23182985	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0316-SU_T1.R1	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.38405797101449296	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0316-SU_T1.R2	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.25	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0316-SU_T1.R3	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.363192182410423	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0316-SU_T1.R4	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.32831325301204806	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0322-SU_T1.R1	p.G13D	p.G13D	c.G38A	12	25398281	25398281	C	T	T	0.00549450549450549	LUAD	True	True	True	Gain-of-function	28572459;22722830;32792368;20147967;26037647	Oncogenic					Trametinib,Cobimetinib,Binimetinib			LEVEL_4	LEVEL_4		33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0322-SU_T1.R2	p.G13D	p.G13D	c.G38A	12	25398281	25398281	C	T	T	0.25897435897435894	LUAD	True	True	True	Gain-of-function	28572459;22722830;32792368;20147967;26037647	Oncogenic					Trametinib,Cobimetinib,Binimetinib			LEVEL_4	LEVEL_4		33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0322-SU_T1.R3	p.G13D	p.G13D	c.G38A	12	25398281	25398281	C	T	T	0.194006309148265	LUAD	True	True	True	Gain-of-function	28572459;22722830;32792368;20147967;26037647	Oncogenic					Trametinib,Cobimetinib,Binimetinib			LEVEL_4	LEVEL_4		33933896;25435214;24746704;23934108										
GRCh37	BRAF	Missense	CRUK0324-SU_T1.R1	p.G469A	p.G469A	c.G1406C	7	140481402	140481402	C	G	G	0.578260869565217	LUAD	True	True	True	Gain-of-function	20179705;26343582;12068308;29247021;28783719;22510884;22773810;16439621;31924734;23833300;31515458;29320312;32540409	Oncogenic					Plixorafenib			LEVEL_4	LEVEL_4		26466569;28659148;28783719;30559419;Janku et al. Abstract# B176, AACR-NCI-EORTC 2017.(http://mct.aacrjournals.org/content/17/1_Supplement/B176);Fuente et al. Abstract# 3006, J. Clin. Oncol. 2023, Vol 41, Suppl 16.(https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.3006)										
GRCh37	BRAF	Missense	CRUK0324-SU_T1.R2	p.G469A	p.G469A	c.G1406C	7	140481402	140481402	C	G	G	0.18666666666666698	LUAD	True	True	True	Gain-of-function	20179705;26343582;12068308;29247021;28783719;22510884;22773810;16439621;31924734;23833300;31515458;29320312;32540409	Oncogenic					Plixorafenib			LEVEL_4	LEVEL_4		26466569;28659148;28783719;30559419;Janku et al. Abstract# B176, AACR-NCI-EORTC 2017.(http://mct.aacrjournals.org/content/17/1_Supplement/B176);Fuente et al. Abstract# 3006, J. Clin. Oncol. 2023, Vol 41, Suppl 16.(https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.3006)										
GRCh37	BRAF	Missense	CRUK0324-SU_T1.R3	p.G469A	p.G469A	c.G1406C	7	140481402	140481402	C	G	G	0.347517730496454	LUAD	True	True	True	Gain-of-function	20179705;26343582;12068308;29247021;28783719;22510884;22773810;16439621;31924734;23833300;31515458;29320312;32540409	Oncogenic					Plixorafenib			LEVEL_4	LEVEL_4		26466569;28659148;28783719;30559419;Janku et al. Abstract# B176, AACR-NCI-EORTC 2017.(http://mct.aacrjournals.org/content/17/1_Supplement/B176);Fuente et al. Abstract# 3006, J. Clin. Oncol. 2023, Vol 41, Suppl 16.(https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.3006)										
GRCh37	KRAS	Missense	CRUK0333-SU_T1.R1	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.45526838966202793	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0333-SU_T1.R2	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.404135338345865	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0333-SU_T1.R3	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.288032454361055	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0337-SU_T1.R1	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.238235294117647	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0337-SU_T1.R2	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.174257425742574	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0337-SU_FLN1	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.522167487684729	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0339-SU_T1.R1	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.616666666666667	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0339-SU_T1.R2	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.598130841121495	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0339-SU_T1.R3	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.73015873015873	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0352-SU_T1.R1	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.667361835245047	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0352-SU_T1.R2	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.624321389793703	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0352-SU_T1.R3	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.657674418604651	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0352-SU_T1.R4	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.39959839357429705	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0352-SU_T1.R5	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.566236811254396	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0352-SU_T1.R6	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.40408626560726396	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0352-SU_T1.R7	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.637281910009183	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0352-SU_FLN1	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.505350772889417	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0361-SU_T1.R1	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.321041214750542	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0361-SU_T1.R2	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.38573743922204207	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0361-SU_T1.R3	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.28024193548387105	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0361-SU_T1.R4	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.46140350877193	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0361-BR_T1.R1	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.24222222222222198	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0361-SU_FLN1	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.0573476702508961	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0361-SU_FLN2	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.0951219512195122	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0361-SU_FLN3	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.132328308207705	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0366-SU_T1.R1	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.153314917127072	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0366-SU_T1.R2	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.588235294117647	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0367-SU_T1.R1	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.0582781456953642	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0367-SU_T1.R3	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.106471816283925	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0367-SU_T1.R4	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.565467625899281	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0367-SU_T1.R5	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.7103825136612021	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0367-SU_T1.R6	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.328685258964143	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0367-SU_T1.R7	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.0575221238938053	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0371-SU_T1.R1	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.25635593220339	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0371-SU_T1.R2	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.280657395701643	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0380-SU_T1.R1	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.160060975609756	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0380-SU_T1.R2	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.26984126984127	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0380-SU_T1.R3	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.123434704830054	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0380-SU_T1.R4	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.136442141623489	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0380-SU_T1.R5	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.213235294117647	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0380-SU_T1.R6	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.157647058823529	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0380-SU_T1.R7	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.0428954423592493	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0380-SU_T1.R8	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.24100719424460396	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	EGFR	In_Frame_Ins	CRUK0388-SU_T1.R1	p.A767delinsASVD	p.A767delinsASVD	c.2300_2301insCAGCGTGGA	7	55249002	55249002	-	CAGCGTGGA	CAGCGTGGA	0.23481781376518202	LUAD	True	True	False	Gain-of-function	23371856;19536777;24353160;21764376;18676761;23912954;23749122;15897572;17686547	Oncogenic	Amivantamab,Amivantamab+Chemotherapy		Poziotinib,CLN-081			Erlotinib,Gefitinib,Afatinib		LEVEL_R1	LEVEL_1	LEVEL_R1	23371856;24065731;19536777;24353160;21764376;18676761;24893891;23328547;15897572;17686547;37870976;32414908;34339292;35820397;27188206;29686424;Heymach et al. Abstract# OA02.06, WCLC 2018.(http://www.jto.org/article/S1556-0864(17)30520-8/fulltext);31467113;Yu et al. Abstract# 9007, ASCO 2022.(https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.9007)										
GRCh37	EGFR	In_Frame_Ins	CRUK0388-SU_T1.R2	p.A767delinsASVD	p.A767delinsASVD	c.2300_2301insCAGCGTGGA	7	55249002	55249002	-	CAGCGTGGA	CAGCGTGGA	0.25968992248062	LUAD	True	True	False	Gain-of-function	23371856;19536777;24353160;21764376;18676761;23912954;23749122;15897572;17686547	Oncogenic	Amivantamab,Amivantamab+Chemotherapy		Poziotinib,CLN-081			Erlotinib,Gefitinib,Afatinib		LEVEL_R1	LEVEL_1	LEVEL_R1	23371856;24065731;19536777;24353160;21764376;18676761;24893891;23328547;15897572;17686547;37870976;32414908;34339292;35820397;27188206;29686424;Heymach et al. Abstract# OA02.06, WCLC 2018.(http://www.jto.org/article/S1556-0864(17)30520-8/fulltext);31467113;Yu et al. Abstract# 9007, ASCO 2022.(https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.9007)										
GRCh37	EGFR	In_Frame_Ins	CRUK0388-SU_T1.R3	p.A767delinsASVD	p.A767delinsASVD	c.2300_2301insCAGCGTGGA	7	55249002	55249002	-	CAGCGTGGA	CAGCGTGGA	0.26556016597510396	LUAD	True	True	False	Gain-of-function	23371856;19536777;24353160;21764376;18676761;23912954;23749122;15897572;17686547	Oncogenic	Amivantamab,Amivantamab+Chemotherapy		Poziotinib,CLN-081			Erlotinib,Gefitinib,Afatinib		LEVEL_R1	LEVEL_1	LEVEL_R1	23371856;24065731;19536777;24353160;21764376;18676761;24893891;23328547;15897572;17686547;37870976;32414908;34339292;35820397;27188206;29686424;Heymach et al. Abstract# OA02.06, WCLC 2018.(http://www.jto.org/article/S1556-0864(17)30520-8/fulltext);31467113;Yu et al. Abstract# 9007, ASCO 2022.(https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.9007)										
GRCh37	EGFR	In_Frame_Ins	CRUK0388-SU_T1.R4	p.A767delinsASVD	p.A767delinsASVD	c.2300_2301insCAGCGTGGA	7	55249002	55249002	-	CAGCGTGGA	CAGCGTGGA	0.236947791164659	LUAD	True	True	False	Gain-of-function	23371856;19536777;24353160;21764376;18676761;23912954;23749122;15897572;17686547	Oncogenic	Amivantamab,Amivantamab+Chemotherapy		Poziotinib,CLN-081			Erlotinib,Gefitinib,Afatinib		LEVEL_R1	LEVEL_1	LEVEL_R1	23371856;24065731;19536777;24353160;21764376;18676761;24893891;23328547;15897572;17686547;37870976;32414908;34339292;35820397;27188206;29686424;Heymach et al. Abstract# OA02.06, WCLC 2018.(http://www.jto.org/article/S1556-0864(17)30520-8/fulltext);31467113;Yu et al. Abstract# 9007, ASCO 2022.(https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.9007)										
GRCh37	EGFR	In_Frame_Ins	CRUK0388-SU_FLN1	p.A767delinsASVD	p.A767delinsASVD	c.2300_2301insCAGCGTGGA	7	55249002	55249002	-	CAGCGTGGA	CAGCGTGGA	0.136986301369863	LUAD	True	True	False	Gain-of-function	23371856;19536777;24353160;21764376;18676761;23912954;23749122;15897572;17686547	Oncogenic	Amivantamab,Amivantamab+Chemotherapy		Poziotinib,CLN-081			Erlotinib,Gefitinib,Afatinib		LEVEL_R1	LEVEL_1	LEVEL_R1	23371856;24065731;19536777;24353160;21764376;18676761;24893891;23328547;15897572;17686547;37870976;32414908;34339292;35820397;27188206;29686424;Heymach et al. Abstract# OA02.06, WCLC 2018.(http://www.jto.org/article/S1556-0864(17)30520-8/fulltext);31467113;Yu et al. Abstract# 9007, ASCO 2022.(https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.9007)										
GRCh37	EGFR	In_Frame_Ins	CRUK0388-SU_FLN2	p.A767delinsASVD	p.A767delinsASVD	c.2300_2301insCAGCGTGGA	7	55249002	55249002	-	CAGCGTGGA	CAGCGTGGA	0.0434782608695652	LUAD	True	True	False	Gain-of-function	23371856;19536777;24353160;21764376;18676761;23912954;23749122;15897572;17686547	Oncogenic	Amivantamab,Amivantamab+Chemotherapy		Poziotinib,CLN-081			Erlotinib,Gefitinib,Afatinib		LEVEL_R1	LEVEL_1	LEVEL_R1	23371856;24065731;19536777;24353160;21764376;18676761;24893891;23328547;15897572;17686547;37870976;32414908;34339292;35820397;27188206;29686424;Heymach et al. Abstract# OA02.06, WCLC 2018.(http://www.jto.org/article/S1556-0864(17)30520-8/fulltext);31467113;Yu et al. Abstract# 9007, ASCO 2022.(https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.9007)										
GRCh37	KRAS	Missense	CRUK0408-SU_T1.R1	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.38439306358381503	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0408-SU_T1.R2	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.5325714285714289	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	EGFR	In_Frame_Ins	CRUK0410-SU_T1.R1	p.M766delinsMASV	p.M766delinsMASV	c.2296_2297insTGGCCAGCG	7	55248998	55248998	-	TGGCCAGCG	TGGCCAGCG	0.24929178470254998	LUAD	True	True	False	Likely Gain-of-function	23371856;26286086;24353160;30255937	Likely Oncogenic	Amivantamab,Amivantamab+Chemotherapy		Poziotinib,CLN-081			Erlotinib,Gefitinib,Afatinib		LEVEL_R1	LEVEL_1	LEVEL_R1	23371856;24065731;19536777;24353160;21764376;18676761;24893891;23328547;15897572;17686547;37870976;32414908;34339292;35820397;27188206;29686424;Heymach et al. Abstract# OA02.06, WCLC 2018.(http://www.jto.org/article/S1556-0864(17)30520-8/fulltext);31467113;Yu et al. Abstract# 9007, ASCO 2022.(https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.9007)										
GRCh37	EGFR	In_Frame_Ins	CRUK0410-SU_T1.R2	p.M766delinsMASV	p.M766delinsMASV	c.2296_2297insTGGCCAGCG	7	55248998	55248998	-	TGGCCAGCG	TGGCCAGCG	0.24919093851132698	LUAD	True	True	False	Likely Gain-of-function	23371856;26286086;24353160;30255937	Likely Oncogenic	Amivantamab,Amivantamab+Chemotherapy		Poziotinib,CLN-081			Erlotinib,Gefitinib,Afatinib		LEVEL_R1	LEVEL_1	LEVEL_R1	23371856;24065731;19536777;24353160;21764376;18676761;24893891;23328547;15897572;17686547;37870976;32414908;34339292;35820397;27188206;29686424;Heymach et al. Abstract# OA02.06, WCLC 2018.(http://www.jto.org/article/S1556-0864(17)30520-8/fulltext);31467113;Yu et al. Abstract# 9007, ASCO 2022.(https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.9007)										
GRCh37	EGFR	In_Frame_Ins	CRUK0410-SU_T1.R3	p.M766delinsMASV	p.M766delinsMASV	c.2296_2297insTGGCCAGCG	7	55248998	55248998	-	TGGCCAGCG	TGGCCAGCG	0.264094955489614	LUAD	True	True	False	Likely Gain-of-function	23371856;26286086;24353160;30255937	Likely Oncogenic	Amivantamab,Amivantamab+Chemotherapy		Poziotinib,CLN-081			Erlotinib,Gefitinib,Afatinib		LEVEL_R1	LEVEL_1	LEVEL_R1	23371856;24065731;19536777;24353160;21764376;18676761;24893891;23328547;15897572;17686547;37870976;32414908;34339292;35820397;27188206;29686424;Heymach et al. Abstract# OA02.06, WCLC 2018.(http://www.jto.org/article/S1556-0864(17)30520-8/fulltext);31467113;Yu et al. Abstract# 9007, ASCO 2022.(https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.9007)										
GRCh37	EGFR	In_Frame_Ins	CRUK0410-SU_T1.R4	p.M766delinsMASV	p.M766delinsMASV	c.2296_2297insTGGCCAGCG	7	55248998	55248998	-	TGGCCAGCG	TGGCCAGCG	0.173728813559322	LUAD	True	True	False	Likely Gain-of-function	23371856;26286086;24353160;30255937	Likely Oncogenic	Amivantamab,Amivantamab+Chemotherapy		Poziotinib,CLN-081			Erlotinib,Gefitinib,Afatinib		LEVEL_R1	LEVEL_1	LEVEL_R1	23371856;24065731;19536777;24353160;21764376;18676761;24893891;23328547;15897572;17686547;37870976;32414908;34339292;35820397;27188206;29686424;Heymach et al. Abstract# OA02.06, WCLC 2018.(http://www.jto.org/article/S1556-0864(17)30520-8/fulltext);31467113;Yu et al. Abstract# 9007, ASCO 2022.(https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.9007)										
GRCh37	EGFR	In_Frame_Ins	CRUK0410-BR_LN1	p.M766delinsMASV	p.M766delinsMASV	c.2296_2297insTGGCCAGCG	7	55248998	55248998	-	TGGCCAGCG	TGGCCAGCG	0.25233644859813104	LUAD	True	True	False	Likely Gain-of-function	23371856;26286086;24353160;30255937	Likely Oncogenic	Amivantamab,Amivantamab+Chemotherapy		Poziotinib,CLN-081			Erlotinib,Gefitinib,Afatinib		LEVEL_R1	LEVEL_1	LEVEL_R1	23371856;24065731;19536777;24353160;21764376;18676761;24893891;23328547;15897572;17686547;37870976;32414908;34339292;35820397;27188206;29686424;Heymach et al. Abstract# OA02.06, WCLC 2018.(http://www.jto.org/article/S1556-0864(17)30520-8/fulltext);31467113;Yu et al. Abstract# 9007, ASCO 2022.(https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.9007)										
GRCh37	KRAS	Missense	CRUK0412-SU_T1.R1	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.43197755960729295	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0412-SU_T1.R2	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.41916167664670706	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0412-SU_T1.R3	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.39449541284403705	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0412-SU_T1.R4	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.43470149253731294	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0412-SU_T1.R5	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.631832797427653	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0412-SU_FLN3	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.00237529691211401	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0413-SU_T1.R1	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.28571428571428603	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0413-SU_T1.R2	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.19450317124735697	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0416-SU_T1.R1	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.528700906344411	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0416-SU_T1.R2	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.22742474916388	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0416-SU_T1.R4	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.234421364985163	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0431-SU_T1.R1	p.Q61R	p.Q61R	c.A182G	12	25380276	25380276	T	C	C	0.210332103321033	LUAD	True	True	True	Gain-of-function	30341394;28572459;34117033;25437878	Oncogenic					Trametinib,Cobimetinib,Binimetinib			LEVEL_4	LEVEL_4		33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0431-SU_T1.R2	p.Q61R	p.Q61R	c.A182G	12	25380276	25380276	T	C	C	0.240208877284595	LUAD	True	True	True	Gain-of-function	30341394;28572459;34117033;25437878	Oncogenic					Trametinib,Cobimetinib,Binimetinib			LEVEL_4	LEVEL_4		33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0445-SU_T1.R1	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.109034267912773	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0445-SU_T1.R2	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.23372781065088802	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0445-SU_T1.R3	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.40125391849529796	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0447-SU_T1.R1	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.341991341991342	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0447-SU_T1.R2	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.504918032786885	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0447-SU_T1.R3	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.43895348837209297	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0450-SU_T1.R1	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.332425068119891	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0450-SU_T1.R2	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.18264840182648398	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0456-SU_T1.R1	p.G12A	p.G12A	c.G35C	12	25398284	25398284	C	G	G	0.149722735674677	LUAD	True	True	True	Gain-of-function	30341394;26662311;26037647;23182985	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0456-SU_T1.R2	p.G12A	p.G12A	c.G35C	12	25398284	25398284	C	G	G	0.153846153846154	LUAD	True	True	True	Gain-of-function	30341394;26662311;26037647;23182985	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0460-SU_T1.R1	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.288311688311688	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0460-SU_T1.R2	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.207627118644068	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0460-SU_T1.R3	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.32124352331606204	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0479-SU_T1.R1	p.G12D	p.G12D	c.G35A	12	25398284	25398284	C	T	T	0.324055666003976	LUAD	True	True	True	Gain-of-function	17349581;19296721;11751631;15093544;30341394;28572459;20570890;32792368;20147967;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)	Oncogenic			RMC-6236		MRTX-1133,Trametinib,ASP3082,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);36472553;33933896;25435214;24746704;23934108;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)										
GRCh37	KRAS	Missense	CRUK0479-SU_T1.R2	p.G12D	p.G12D	c.G35A	12	25398284	25398284	C	T	T	0.41743970315398904	LUAD	True	True	True	Gain-of-function	17349581;19296721;11751631;15093544;30341394;28572459;20570890;32792368;20147967;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)	Oncogenic			RMC-6236		MRTX-1133,Trametinib,ASP3082,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);36472553;33933896;25435214;24746704;23934108;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)										
GRCh37	KRAS	Missense	CRUK0479-SU_T1.R3	p.G12D	p.G12D	c.G35A	12	25398284	25398284	C	T	T	0.33516483516483503	LUAD	True	True	True	Gain-of-function	17349581;19296721;11751631;15093544;30341394;28572459;20570890;32792368;20147967;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)	Oncogenic			RMC-6236		MRTX-1133,Trametinib,ASP3082,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);36472553;33933896;25435214;24746704;23934108;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)										
GRCh37	KRAS	Missense	CRUK0479-SU_T1.R4	p.G12D	p.G12D	c.G35A	12	25398284	25398284	C	T	T	0.20745920745920698	LUAD	True	True	True	Gain-of-function	17349581;19296721;11751631;15093544;30341394;28572459;20570890;32792368;20147967;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)	Oncogenic			RMC-6236		MRTX-1133,Trametinib,ASP3082,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);36472553;33933896;25435214;24746704;23934108;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)										
GRCh37	EGFR	In_Frame_Del	CRUK0492-SU_T1.R1			c.2234_2234delins-GGAATTAAGAGAAGC	7	55242464	55242464	A	-GGAATTAAGAGAAGC	-GGAATTAAGAGAAGC	0.089041095890411	LUAD	True	True	True	Likely Gain-of-function	15329413;18000506;15118125;34526717;19536777;18458038;15118073;22019513;23566546;23559152;24457318;22760226;23749122;17192902	Likely Oncogenic	Erlotinib,Osimertinib+Chemotherapy,Erlotinib+Ramucirumab,Afatinib,Gefitinib,Osimertinib,Dacomitinib	Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		22285168;27987585;29151359;37937763;31751012;30659024;23816960;22452895;25589191;20022809;19692680;21670455;22370314;31682542;20573926;29864379;28958502;37879444;37689979;38369013;31661465;34548309;30057690;34084213;38924756;34028784;37710001										
GRCh37	EGFR	In_Frame_Del	CRUK0492-SU_T1.R2			c.2234_2234delins-GGAATTAAGAGAAGC	7	55242464	55242464	A	-GGAATTAAGAGAAGC	-GGAATTAAGAGAAGC	0.0884109916367981	LUAD	True	True	True	Likely Gain-of-function	15329413;18000506;15118125;34526717;19536777;18458038;15118073;22019513;23566546;23559152;24457318;22760226;23749122;17192902	Likely Oncogenic	Erlotinib,Osimertinib+Chemotherapy,Erlotinib+Ramucirumab,Afatinib,Gefitinib,Osimertinib,Dacomitinib	Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		22285168;27987585;29151359;37937763;31751012;30659024;23816960;22452895;25589191;20022809;19692680;21670455;22370314;31682542;20573926;29864379;28958502;37879444;37689979;38369013;31661465;34548309;30057690;34084213;38924756;34028784;37710001										
GRCh37	EGFR	In_Frame_Del	CRUK0492-SU_T1.R3			c.2234_2234delins-GGAATTAAGAGAAGC	7	55242464	55242464	A	-GGAATTAAGAGAAGC	-GGAATTAAGAGAAGC	0.0760869565217391	LUAD	True	True	True	Likely Gain-of-function	15329413;18000506;15118125;34526717;19536777;18458038;15118073;22019513;23566546;23559152;24457318;22760226;23749122;17192902	Likely Oncogenic	Erlotinib,Osimertinib+Chemotherapy,Erlotinib+Ramucirumab,Afatinib,Gefitinib,Osimertinib,Dacomitinib	Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		22285168;27987585;29151359;37937763;31751012;30659024;23816960;22452895;25589191;20022809;19692680;21670455;22370314;31682542;20573926;29864379;28958502;37879444;37689979;38369013;31661465;34548309;30057690;34084213;38924756;34028784;37710001										
GRCh37	KRAS	Missense	CRUK0497-SU_T1.R1	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.6917647058823531	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0497-SU_T1.R2	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.8028571428571429	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0497-SU_T1.R3	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.8227383863080691	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0497-BR_T1.FR1	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.7059829059829059	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0504-SU_T1.R1	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.462151394422311	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0504-SU_T1.R2	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.557432432432432	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0512-SU_T1.R1	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.36896551724137894	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0512-SU_T1.R2	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.3867924528301889	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0512-SU_T1.R3	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.249221183800623	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0512-SU_T1.R4	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.379716981132075	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0513-SU_T1.R1	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.8028846153846151	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0513-SU_T1.R2	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.752475247524752	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0513-SU_T1.R3	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.159883720930233	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0513-SU_T1.R4	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.708333333333333	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0513-SU_T1.R5	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.0550724637681159	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	EGFR	In_Frame_Del	CRUK0520-SU_T1.R1			c.2234_2234delins-GGAATTAAGAGAAGC	7	55242464	55242464	A	-GGAATTAAGAGAAGC	-GGAATTAAGAGAAGC	0.1364522417154	LUAD	True	True	True	Likely Gain-of-function	15329413;18000506;15118125;34526717;19536777;18458038;15118073;22019513;23566546;23559152;24457318;22760226;23749122;17192902	Likely Oncogenic	Erlotinib,Osimertinib+Chemotherapy,Erlotinib+Ramucirumab,Afatinib,Gefitinib,Osimertinib,Dacomitinib	Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		22285168;27987585;29151359;37937763;31751012;30659024;23816960;22452895;25589191;20022809;19692680;21670455;22370314;31682542;20573926;29864379;28958502;37879444;37689979;38369013;31661465;34548309;30057690;34084213;38924756;34028784;37710001										
GRCh37	EGFR	In_Frame_Del	CRUK0520-SU_T1.R2			c.2234_2234delins-GGAATTAAGAGAAGC	7	55242464	55242464	A	-GGAATTAAGAGAAGC	-GGAATTAAGAGAAGC	0.138198757763975	LUAD	True	True	True	Likely Gain-of-function	15329413;18000506;15118125;34526717;19536777;18458038;15118073;22019513;23566546;23559152;24457318;22760226;23749122;17192902	Likely Oncogenic	Erlotinib,Osimertinib+Chemotherapy,Erlotinib+Ramucirumab,Afatinib,Gefitinib,Osimertinib,Dacomitinib	Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		22285168;27987585;29151359;37937763;31751012;30659024;23816960;22452895;25589191;20022809;19692680;21670455;22370314;31682542;20573926;29864379;28958502;37879444;37689979;38369013;31661465;34548309;30057690;34084213;38924756;34028784;37710001										
GRCh37	EGFR	In_Frame_Del	CRUK0525-SU_T1.R1			c.2235_2235delins-GAATTAAGAGAAGCA	7	55242465	55242465	G	-GAATTAAGAGAAGCA	-GAATTAAGAGAAGCA	0.165067178502879	LUAD	True	True	True	Likely Gain-of-function	15329413;18000506;15118125;34526717;19536777;18458038;15118073;22019513;23566546;23559152;24457318;22760226;23749122;17192902	Likely Oncogenic	Erlotinib,Osimertinib+Chemotherapy,Erlotinib+Ramucirumab,Afatinib,Gefitinib,Osimertinib,Dacomitinib	Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		22285168;27987585;29151359;37937763;31751012;30659024;23816960;22452895;25589191;20022809;19692680;21670455;22370314;31682542;20573926;29864379;28958502;37879444;37689979;38369013;31661465;34548309;30057690;34084213;38924756;34028784;37710001										
GRCh37	EGFR	In_Frame_Del	CRUK0525-SU_T1.R2			c.2235_2235delins-GAATTAAGAGAAGCA	7	55242465	55242465	G	-GAATTAAGAGAAGCA	-GAATTAAGAGAAGCA	0.203703703703704	LUAD	True	True	True	Likely Gain-of-function	15329413;18000506;15118125;34526717;19536777;18458038;15118073;22019513;23566546;23559152;24457318;22760226;23749122;17192902	Likely Oncogenic	Erlotinib,Osimertinib+Chemotherapy,Erlotinib+Ramucirumab,Afatinib,Gefitinib,Osimertinib,Dacomitinib	Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		22285168;27987585;29151359;37937763;31751012;30659024;23816960;22452895;25589191;20022809;19692680;21670455;22370314;31682542;20573926;29864379;28958502;37879444;37689979;38369013;31661465;34548309;30057690;34084213;38924756;34028784;37710001										
GRCh37	KRAS	Missense	CRUK0530-SU_T1.R1	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.17065868263473097	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0530-SU_T1.R2	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.43886462882096094	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0530-BR_T1.R1	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.0933333333333333	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0530-SU_FLN1	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.212034383954155	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0530-SU_FLN2	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.179487179487179	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0533-SU_T1.R1	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.7836990595611291	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0533-SU_T1.R2	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.685950413223141	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0533-SU_T1.R3	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.8844984802431609	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0533-SU_T1.R4	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.7976190476190479	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0537-SU_T1.R1	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.22245762711864397	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0537-SU_T1.R2	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.15	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0537-BR_T1.R1	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.197590361445783	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0541-SU_T1.R1	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.52882703777336	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0541-SU_T1.R2	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.5349922239502329	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0543-SU_T1.R1	p.G12D	p.G12D	c.G35A	12	25398284	25398284	C	T	T	0.514851485148515	LUAD	True	True	True	Gain-of-function	17349581;19296721;11751631;15093544;30341394;28572459;20570890;32792368;20147967;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)	Oncogenic			RMC-6236		MRTX-1133,Trametinib,ASP3082,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);36472553;33933896;25435214;24746704;23934108;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)										
GRCh37	KRAS	Missense	CRUK0543-SU_T1.R2	p.G12D	p.G12D	c.G35A	12	25398284	25398284	C	T	T	0.31701030927835	LUAD	True	True	True	Gain-of-function	17349581;19296721;11751631;15093544;30341394;28572459;20570890;32792368;20147967;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)	Oncogenic			RMC-6236		MRTX-1133,Trametinib,ASP3082,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);36472553;33933896;25435214;24746704;23934108;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)										
GRCh37	KRAS	Missense	CRUK0543-SU_T1.R3	p.G12D	p.G12D	c.G35A	12	25398284	25398284	C	T	T	0.48148148148148107	LUAD	True	True	True	Gain-of-function	17349581;19296721;11751631;15093544;30341394;28572459;20570890;32792368;20147967;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)	Oncogenic			RMC-6236		MRTX-1133,Trametinib,ASP3082,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);36472553;33933896;25435214;24746704;23934108;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)										
GRCh37	KRAS	Missense	CRUK0543-SU_T1.R4	p.G12D	p.G12D	c.G35A	12	25398284	25398284	C	T	T	0.45337620578778104	LUAD	True	True	True	Gain-of-function	17349581;19296721;11751631;15093544;30341394;28572459;20570890;32792368;20147967;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)	Oncogenic			RMC-6236		MRTX-1133,Trametinib,ASP3082,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);36472553;33933896;25435214;24746704;23934108;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)										
GRCh37	KRAS	Missense	CRUK0543-SU_T1.R5	p.G12D	p.G12D	c.G35A	12	25398284	25398284	C	T	T	0.46641074856046105	LUAD	True	True	True	Gain-of-function	17349581;19296721;11751631;15093544;30341394;28572459;20570890;32792368;20147967;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)	Oncogenic			RMC-6236		MRTX-1133,Trametinib,ASP3082,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);36472553;33933896;25435214;24746704;23934108;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)										
GRCh37	KRAS	Missense	CRUK0543-SU_T1.R6	p.G12D	p.G12D	c.G35A	12	25398284	25398284	C	T	T	0.45336225596529295	LUAD	True	True	True	Gain-of-function	17349581;19296721;11751631;15093544;30341394;28572459;20570890;32792368;20147967;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)	Oncogenic			RMC-6236		MRTX-1133,Trametinib,ASP3082,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);36472553;33933896;25435214;24746704;23934108;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)										
GRCh37	KRAS	Missense	CRUK0543-SU_T1.R7	p.G12D	p.G12D	c.G35A	12	25398284	25398284	C	T	T	0.38983050847457595	LUAD	True	True	True	Gain-of-function	17349581;19296721;11751631;15093544;30341394;28572459;20570890;32792368;20147967;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)	Oncogenic			RMC-6236		MRTX-1133,Trametinib,ASP3082,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);36472553;33933896;25435214;24746704;23934108;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)										
GRCh37	KRAS	Missense	CRUK0543-SU_FLN1	p.G12D	p.G12D	c.G35A	12	25398284	25398284	C	T	T	0.321041214750542	LUAD	True	True	True	Gain-of-function	17349581;19296721;11751631;15093544;30341394;28572459;20570890;32792368;20147967;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)	Oncogenic			RMC-6236		MRTX-1133,Trametinib,ASP3082,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);36472553;33933896;25435214;24746704;23934108;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)										
GRCh37	KRAS	Missense	CRUK0543-SU_FLN3	p.G12D	p.G12D	c.G35A	12	25398284	25398284	C	T	T	0.440789473684211	LUAD	True	True	True	Gain-of-function	17349581;19296721;11751631;15093544;30341394;28572459;20570890;32792368;20147967;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)	Oncogenic			RMC-6236		MRTX-1133,Trametinib,ASP3082,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);36472553;33933896;25435214;24746704;23934108;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)										
GRCh37	KRAS	Missense	CRUK0543-SU_FLN5	p.G12D	p.G12D	c.G35A	12	25398284	25398284	C	T	T	0.16	LUAD	True	True	True	Gain-of-function	17349581;19296721;11751631;15093544;30341394;28572459;20570890;32792368;20147967;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)	Oncogenic			RMC-6236		MRTX-1133,Trametinib,ASP3082,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);36472553;33933896;25435214;24746704;23934108;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)										
GRCh37	KRAS	Missense	CRUK0548-SU_T1.R1	p.G12D	p.G12D	c.G35A	12	25398284	25398284	C	T	T	0.291358024691358	LUAD	True	True	True	Gain-of-function	17349581;19296721;11751631;15093544;30341394;28572459;20570890;32792368;20147967;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)	Oncogenic			RMC-6236		MRTX-1133,Trametinib,ASP3082,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);36472553;33933896;25435214;24746704;23934108;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)										
GRCh37	KRAS	Missense	CRUK0548-SU_T1.R2	p.G12D	p.G12D	c.G35A	12	25398284	25398284	C	T	T	0.323809523809524	LUAD	True	True	True	Gain-of-function	17349581;19296721;11751631;15093544;30341394;28572459;20570890;32792368;20147967;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)	Oncogenic			RMC-6236		MRTX-1133,Trametinib,ASP3082,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);36472553;33933896;25435214;24746704;23934108;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)										
GRCh37	KRAS	Missense	CRUK0552-SU_T1.R1	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.412130637636081	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0552-SU_T1.R2	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.4895833333333329	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0552-SU_T1.R3	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.40148148148148105	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0552-BR_LN1	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.5309033280507129	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	EGFR	Missense	CRUK0559-SU_LN1	p.R776C	p.R776C	c.C2326T	7	55249028	55249028	C	T	T	0.319693094629156	LUAD	True	True	True	Gain-of-function	19147750	Likely Oncogenic																					
GRCh37	EGFR	Missense	CRUK0559-SU_LN2	p.R776C	p.R776C	c.C2326T	7	55249028	55249028	C	T	T	0.364820846905537	LUAD	True	True	True	Gain-of-function	19147750	Likely Oncogenic																					
GRCh37	EGFR	Missense	CRUK0559-SU_LN3	p.R776C	p.R776C	c.C2326T	7	55249028	55249028	C	T	T	0.260387811634349	LUAD	True	True	True	Gain-of-function	19147750	Likely Oncogenic																					
GRCh37	EGFR	Missense	CRUK0559-SU_T1.R1	p.R776C	p.R776C	c.C2326T	7	55249028	55249028	C	T	T	0.81651376146789	LUAD	True	True	True	Gain-of-function	19147750	Likely Oncogenic																					
GRCh37	EGFR	Missense	CRUK0559-SU_T1.R2	p.R776C	p.R776C	c.C2326T	7	55249028	55249028	C	T	T	0.571125265392781	LUAD	True	True	True	Gain-of-function	19147750	Likely Oncogenic																					
GRCh37	EGFR	Missense	CRUK0559-SU_T1.R3	p.R776C	p.R776C	c.C2326T	7	55249028	55249028	C	T	T	0.5152749490835029	LUAD	True	True	True	Gain-of-function	19147750	Likely Oncogenic																					
GRCh37	EGFR	Missense	CRUK0559-SU_T1.R4	p.R776C	p.R776C	c.C2326T	7	55249028	55249028	C	T	T	0.652650822669104	LUAD	True	True	True	Gain-of-function	19147750	Likely Oncogenic																					
GRCh37	EGFR	Missense	CRUK0559-SU_T1.R5	p.R776C	p.R776C	c.C2326T	7	55249028	55249028	C	T	T	0.719298245614035	LUAD	True	True	True	Gain-of-function	19147750	Likely Oncogenic																					
GRCh37	EGFR	Missense	CRUK0559-BR_T1.R1	p.R776C	p.R776C	c.C2326T	7	55249028	55249028	C	T	T	0.35307017543859603	LUAD	True	True	True	Gain-of-function	19147750	Likely Oncogenic																					
GRCh37	EGFR	Missense	CRUK0559-SU_FLN1	p.R776C	p.R776C	c.C2326T	7	55249028	55249028	C	T	T	0.32409381663113	LUAD	True	True	True	Gain-of-function	19147750	Likely Oncogenic																					
GRCh37	EGFR	Missense	CRUK0559-SU_LN1	p.L858R	p.L858R	c.T2573G	7	55259515	55259515	T	G	G	0.310734463276836	LUAD	True	True	True	Gain-of-function	15329413;15118073;15118125;34526717	Oncogenic	Erlotinib,Osimertinib+Chemotherapy,Erlotinib+Ramucirumab,Afatinib,Gefitinib,Osimertinib,Dacomitinib	Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		22285168;27987585;29151359;37937763;31751012;30659024;23816960;22452895;25589191;20022809;19692680;21670455;22370314;31682542;20573926;29864379;28958502;37879444;37689979;38369013;31661465;34548309;30057690;34084213;38924756;34028784;37710001										
GRCh37	EGFR	Missense	CRUK0559-SU_LN2	p.L858R	p.L858R	c.T2573G	7	55259515	55259515	T	G	G	0.414686825053996	LUAD	True	True	True	Gain-of-function	15329413;15118073;15118125;34526717	Oncogenic	Erlotinib,Osimertinib+Chemotherapy,Erlotinib+Ramucirumab,Afatinib,Gefitinib,Osimertinib,Dacomitinib	Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		22285168;27987585;29151359;37937763;31751012;30659024;23816960;22452895;25589191;20022809;19692680;21670455;22370314;31682542;20573926;29864379;28958502;37879444;37689979;38369013;31661465;34548309;30057690;34084213;38924756;34028784;37710001										
GRCh37	EGFR	Missense	CRUK0559-SU_LN3	p.L858R	p.L858R	c.T2573G	7	55259515	55259515	T	G	G	0.27991452991453003	LUAD	True	True	True	Gain-of-function	15329413;15118073;15118125;34526717	Oncogenic	Erlotinib,Osimertinib+Chemotherapy,Erlotinib+Ramucirumab,Afatinib,Gefitinib,Osimertinib,Dacomitinib	Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		22285168;27987585;29151359;37937763;31751012;30659024;23816960;22452895;25589191;20022809;19692680;21670455;22370314;31682542;20573926;29864379;28958502;37879444;37689979;38369013;31661465;34548309;30057690;34084213;38924756;34028784;37710001										
GRCh37	EGFR	Missense	CRUK0559-SU_T1.R1	p.L858R	p.L858R	c.T2573G	7	55259515	55259515	T	G	G	0.804245283018868	LUAD	True	True	True	Gain-of-function	15329413;15118073;15118125;34526717	Oncogenic	Erlotinib,Osimertinib+Chemotherapy,Erlotinib+Ramucirumab,Afatinib,Gefitinib,Osimertinib,Dacomitinib	Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		22285168;27987585;29151359;37937763;31751012;30659024;23816960;22452895;25589191;20022809;19692680;21670455;22370314;31682542;20573926;29864379;28958502;37879444;37689979;38369013;31661465;34548309;30057690;34084213;38924756;34028784;37710001										
GRCh37	EGFR	Missense	CRUK0559-SU_T1.R2	p.L858R	p.L858R	c.T2573G	7	55259515	55259515	T	G	G	0.551920341394026	LUAD	True	True	True	Gain-of-function	15329413;15118073;15118125;34526717	Oncogenic	Erlotinib,Osimertinib+Chemotherapy,Erlotinib+Ramucirumab,Afatinib,Gefitinib,Osimertinib,Dacomitinib	Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		22285168;27987585;29151359;37937763;31751012;30659024;23816960;22452895;25589191;20022809;19692680;21670455;22370314;31682542;20573926;29864379;28958502;37879444;37689979;38369013;31661465;34548309;30057690;34084213;38924756;34028784;37710001										
GRCh37	EGFR	Missense	CRUK0559-SU_T1.R3	p.L858R	p.L858R	c.T2573G	7	55259515	55259515	T	G	G	0.522508038585209	LUAD	True	True	True	Gain-of-function	15329413;15118073;15118125;34526717	Oncogenic	Erlotinib,Osimertinib+Chemotherapy,Erlotinib+Ramucirumab,Afatinib,Gefitinib,Osimertinib,Dacomitinib	Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		22285168;27987585;29151359;37937763;31751012;30659024;23816960;22452895;25589191;20022809;19692680;21670455;22370314;31682542;20573926;29864379;28958502;37879444;37689979;38369013;31661465;34548309;30057690;34084213;38924756;34028784;37710001										
GRCh37	EGFR	Missense	CRUK0559-SU_T1.R4	p.L858R	p.L858R	c.T2573G	7	55259515	55259515	T	G	G	0.605594405594406	LUAD	True	True	True	Gain-of-function	15329413;15118073;15118125;34526717	Oncogenic	Erlotinib,Osimertinib+Chemotherapy,Erlotinib+Ramucirumab,Afatinib,Gefitinib,Osimertinib,Dacomitinib	Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		22285168;27987585;29151359;37937763;31751012;30659024;23816960;22452895;25589191;20022809;19692680;21670455;22370314;31682542;20573926;29864379;28958502;37879444;37689979;38369013;31661465;34548309;30057690;34084213;38924756;34028784;37710001										
GRCh37	EGFR	Missense	CRUK0559-SU_T1.R5	p.L858R	p.L858R	c.T2573G	7	55259515	55259515	T	G	G	0.737076648841355	LUAD	True	True	True	Gain-of-function	15329413;15118073;15118125;34526717	Oncogenic	Erlotinib,Osimertinib+Chemotherapy,Erlotinib+Ramucirumab,Afatinib,Gefitinib,Osimertinib,Dacomitinib	Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		22285168;27987585;29151359;37937763;31751012;30659024;23816960;22452895;25589191;20022809;19692680;21670455;22370314;31682542;20573926;29864379;28958502;37879444;37689979;38369013;31661465;34548309;30057690;34084213;38924756;34028784;37710001										
GRCh37	EGFR	Missense	CRUK0559-BR_T1.R1	p.L858R	p.L858R	c.T2573G	7	55259515	55259515	T	G	G	0.30633802816901395	LUAD	True	True	True	Gain-of-function	15329413;15118073;15118125;34526717	Oncogenic	Erlotinib,Osimertinib+Chemotherapy,Erlotinib+Ramucirumab,Afatinib,Gefitinib,Osimertinib,Dacomitinib	Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		22285168;27987585;29151359;37937763;31751012;30659024;23816960;22452895;25589191;20022809;19692680;21670455;22370314;31682542;20573926;29864379;28958502;37879444;37689979;38369013;31661465;34548309;30057690;34084213;38924756;34028784;37710001										
GRCh37	EGFR	Missense	CRUK0559-SU_FLN1	p.L858R	p.L858R	c.T2573G	7	55259515	55259515	T	G	G	0.335779816513761	LUAD	True	True	True	Gain-of-function	15329413;15118073;15118125;34526717	Oncogenic	Erlotinib,Osimertinib+Chemotherapy,Erlotinib+Ramucirumab,Afatinib,Gefitinib,Osimertinib,Dacomitinib	Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		22285168;27987585;29151359;37937763;31751012;30659024;23816960;22452895;25589191;20022809;19692680;21670455;22370314;31682542;20573926;29864379;28958502;37879444;37689979;38369013;31661465;34548309;30057690;34084213;38924756;34028784;37710001										
GRCh37	KRAS	Missense	CRUK0569-SU_T1.R1	p.G13D	p.G13D	c.G38A	12	25398281	25398281	C	T	T	0.15192743764172303	LUAD	True	True	True	Gain-of-function	28572459;22722830;32792368;20147967;26037647	Oncogenic					Trametinib,Cobimetinib,Binimetinib			LEVEL_4	LEVEL_4		33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0569-SU_T1.R2	p.G13D	p.G13D	c.G38A	12	25398281	25398281	C	T	T	0.0294117647058824	LUAD	True	True	True	Gain-of-function	28572459;22722830;32792368;20147967;26037647	Oncogenic					Trametinib,Cobimetinib,Binimetinib			LEVEL_4	LEVEL_4		33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0570-SU_T1.R1	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.34467120181405897	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0570-SU_T1.R2	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.33928571428571397	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0572-SU_T1.R1	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.0574712643678161	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0572-SU_T1.R2	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.0822622107969152	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0572-SU_T1.R3	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.111464968152866	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0572-SU_T1.R4	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.0647482014388489	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0572-SU_FLN1	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.114018691588785	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0572-SU_FLN2	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.162962962962963	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0573-SU_T1.R1	p.G12D	p.G12D	c.G35A	12	25398284	25398284	C	T	T	0.5618221258134489	LUAD	True	True	True	Gain-of-function	17349581;19296721;11751631;15093544;30341394;28572459;20570890;32792368;20147967;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)	Oncogenic			RMC-6236		MRTX-1133,Trametinib,ASP3082,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);36472553;33933896;25435214;24746704;23934108;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)										
GRCh37	KRAS	Missense	CRUK0573-SU_T1.R2	p.G12D	p.G12D	c.G35A	12	25398284	25398284	C	T	T	0.368070953436807	LUAD	True	True	True	Gain-of-function	17349581;19296721;11751631;15093544;30341394;28572459;20570890;32792368;20147967;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)	Oncogenic			RMC-6236		MRTX-1133,Trametinib,ASP3082,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);36472553;33933896;25435214;24746704;23934108;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)										
GRCh37	KRAS	Missense	CRUK0573-SU_T1.R3	p.G12D	p.G12D	c.G35A	12	25398284	25398284	C	T	T	0.5530145530145529	LUAD	True	True	True	Gain-of-function	17349581;19296721;11751631;15093544;30341394;28572459;20570890;32792368;20147967;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)	Oncogenic			RMC-6236		MRTX-1133,Trametinib,ASP3082,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);36472553;33933896;25435214;24746704;23934108;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)										
GRCh37	KRAS	Missense	CRUK0573-SU_T1.R4	p.G12D	p.G12D	c.G35A	12	25398284	25398284	C	T	T	0.525301204819277	LUAD	True	True	True	Gain-of-function	17349581;19296721;11751631;15093544;30341394;28572459;20570890;32792368;20147967;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)	Oncogenic			RMC-6236		MRTX-1133,Trametinib,ASP3082,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);36472553;33933896;25435214;24746704;23934108;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)										
GRCh37	KRAS	Missense	CRUK0581-SU_T1.R1	p.G12D	p.G12D	c.G35A	12	25398284	25398284	C	T	T	0.0828025477707006	LUAD	True	True	True	Gain-of-function	17349581;19296721;11751631;15093544;30341394;28572459;20570890;32792368;20147967;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)	Oncogenic			RMC-6236		MRTX-1133,Trametinib,ASP3082,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);36472553;33933896;25435214;24746704;23934108;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)										
GRCh37	KRAS	Missense	CRUK0581-SU_T1.R2	p.G12D	p.G12D	c.G35A	12	25398284	25398284	C	T	T	0.032967032967032996	LUAD	True	True	True	Gain-of-function	17349581;19296721;11751631;15093544;30341394;28572459;20570890;32792368;20147967;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)	Oncogenic			RMC-6236		MRTX-1133,Trametinib,ASP3082,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);36472553;33933896;25435214;24746704;23934108;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)										
GRCh37	KRAS	Missense	CRUK0588-SU_T1.R1	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.116455696202532	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0588-SU_T1.R2	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.650485436893204	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0588-SU_T1.R3	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.14379084967320302	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0588-SU_T1.R4	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.33086876155267997	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0588-SU_T1.R5	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.0698689956331878	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	BRAF	Missense	CRUK0592-SU_T1.R1	p.G466A	p.G466A	c.G1397C	7	140481411	140481411	C	G	G	0.441823899371069	LUAD	True	True	True	Gain-of-function	31924734;31959346;12068308;28783719;33669326;15035987;28481359;Wolf et al. Abstract# 1387p, Annals of Oncology 2020.(https://www.annalsofoncology.org/article/S0923-7534%2820%2941697-7/fulltext)	Oncogenic																					
GRCh37	BRAF	Missense	CRUK0592-SU_T1.R2	p.G466A	p.G466A	c.G1397C	7	140481411	140481411	C	G	G	0.309885931558935	LUAD	True	True	True	Gain-of-function	31924734;31959346;12068308;28783719;33669326;15035987;28481359;Wolf et al. Abstract# 1387p, Annals of Oncology 2020.(https://www.annalsofoncology.org/article/S0923-7534%2820%2941697-7/fulltext)	Oncogenic																					
GRCh37	BRAF	Missense	CRUK0592-SU_T1.R3	p.G466A	p.G466A	c.G1397C	7	140481411	140481411	C	G	G	0.389002036659878	LUAD	True	True	True	Gain-of-function	31924734;31959346;12068308;28783719;33669326;15035987;28481359;Wolf et al. Abstract# 1387p, Annals of Oncology 2020.(https://www.annalsofoncology.org/article/S0923-7534%2820%2941697-7/fulltext)	Oncogenic																					
GRCh37	KRAS	Missense	CRUK0607-SU_T1.R1	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.27083333333333304	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0607-SU_T1.R2	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.23446327683615803	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0607-SU_T1.R3	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.262472885032538	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0610-SU_T1.R1	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.0826923076923077	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0610-SU_T1.R2	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.12165450121654499	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0610-SU_T1.R3	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.195255474452555	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0610-SU_T1.R4	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.0982532751091703	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0620-SU_FLN2	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.515260323159785	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0620-SU_FLN3	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.4475	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0620-SU_LN1	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.557874762808349	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0620-SU_T1.R5	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.479427549194991	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0620-SU_T2.R1	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.6652542372881359	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0620-SU_T2.R2	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.536704730831974	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0620-SU_T2.R3	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.6070686070686071	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0620-SU_T2.R4	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.7277777777777779	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	BRAF	Missense	CRUK0625-SU_T1.R1	p.G466V	p.G466V	c.G1397T	7	140481411	140481411	C	A	A	0.219178082191781	LUAD	True	True	True	Gain-of-function	30104724;31959346;26498038;22649091;26090892;16364920;27523909;28783719;15046639;28481359;16439621;31924734;31515458;24202393;30559419;15035987	Oncogenic																					
GRCh37	BRAF	Missense	CRUK0625-SU_T1.R2	p.G466V	p.G466V	c.G1397T	7	140481411	140481411	C	A	A	0.35454545454545505	LUAD	True	True	True	Gain-of-function	30104724;31959346;26498038;22649091;26090892;16364920;27523909;28783719;15046639;28481359;16439621;31924734;31515458;24202393;30559419;15035987	Oncogenic																					
GRCh37	BRAF	Missense	CRUK0625-SU_T1.R3	p.G466V	p.G466V	c.G1397T	7	140481411	140481411	C	A	A	0.29067641681901296	LUAD	True	True	True	Gain-of-function	30104724;31959346;26498038;22649091;26090892;16364920;27523909;28783719;15046639;28481359;16439621;31924734;31515458;24202393;30559419;15035987	Oncogenic																					
GRCh37	BRAF	Missense	CRUK0625-SU_FLN1	p.G466V	p.G466V	c.G1397T	7	140481411	140481411	C	A	A	0.13031914893617	LUAD	True	True	True	Gain-of-function	30104724;31959346;26498038;22649091;26090892;16364920;27523909;28783719;15046639;28481359;16439621;31924734;31515458;24202393;30559419;15035987	Oncogenic																					
GRCh37	KRAS	Missense	CRUK0628-SU_T1.R1	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.0860215053763441	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0628-SU_T1.R2	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.174147217235189	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0628-SU_T1.R4	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.327077747989276	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0633-SU_T1.R1	p.G12A	p.G12A	c.G35C	12	25398284	25398284	C	G	G	0.14928425357873198	LUAD	True	True	True	Gain-of-function	30341394;26662311;26037647;23182985	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0633-SU_T1.R2	p.G12A	p.G12A	c.G35C	12	25398284	25398284	C	G	G	0.157281553398058	LUAD	True	True	True	Gain-of-function	30341394;26662311;26037647;23182985	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0633-SU_T1.R3	p.G12A	p.G12A	c.G35C	12	25398284	25398284	C	G	G	0.29444444444444395	LUAD	True	True	True	Gain-of-function	30341394;26662311;26037647;23182985	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0642-SU_T1.R1	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.0741687979539642	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0642-SU_T1.R2	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.10149253731343301	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0643-SU_T1.R1	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.05625	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0643-SU_T1.R2	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.171641791044776	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0650-SU_T1.R1	p.Q22K	p.Q22K	c.C64A	12	25398255	25398255	G	T	T	0.903052064631957	LUAD	True	True	True	Gain-of-function	23059812;20570890;26284123;34117033;20949621;11095964	Oncogenic					Trametinib,Cobimetinib,Binimetinib			LEVEL_4	LEVEL_4		33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0650-SU_T1.R2	p.Q22K	p.Q22K	c.C64A	12	25398255	25398255	G	T	T	0.855	LUAD	True	True	True	Gain-of-function	23059812;20570890;26284123;34117033;20949621;11095964	Oncogenic					Trametinib,Cobimetinib,Binimetinib			LEVEL_4	LEVEL_4		33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0650-SU_T1.R3	p.Q22K	p.Q22K	c.C64A	12	25398255	25398255	G	T	T	0.816120906801008	LUAD	True	True	True	Gain-of-function	23059812;20570890;26284123;34117033;20949621;11095964	Oncogenic					Trametinib,Cobimetinib,Binimetinib			LEVEL_4	LEVEL_4		33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0666-SU_T1.R1	p.G12D	p.G12D	c.G35A	12	25398284	25398284	C	T	T	0.476284584980237	LUAD	True	True	True	Gain-of-function	17349581;19296721;11751631;15093544;30341394;28572459;20570890;32792368;20147967;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)	Oncogenic			RMC-6236		MRTX-1133,Trametinib,ASP3082,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);36472553;33933896;25435214;24746704;23934108;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)										
GRCh37	KRAS	Missense	CRUK0666-SU_T1.R2	p.G12D	p.G12D	c.G35A	12	25398284	25398284	C	T	T	0.29757785467128	LUAD	True	True	True	Gain-of-function	17349581;19296721;11751631;15093544;30341394;28572459;20570890;32792368;20147967;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)	Oncogenic			RMC-6236		MRTX-1133,Trametinib,ASP3082,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);36472553;33933896;25435214;24746704;23934108;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)										
GRCh37	KRAS	Missense	CRUK0666-SU_T1.R3	p.G12D	p.G12D	c.G35A	12	25398284	25398284	C	T	T	0.41882352941176504	LUAD	True	True	True	Gain-of-function	17349581;19296721;11751631;15093544;30341394;28572459;20570890;32792368;20147967;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)	Oncogenic			RMC-6236		MRTX-1133,Trametinib,ASP3082,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);36472553;33933896;25435214;24746704;23934108;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)										
GRCh37	KRAS	Missense	CRUK0666-SU_T1.R4	p.G12D	p.G12D	c.G35A	12	25398284	25398284	C	T	T	0.42369020501139	LUAD	True	True	True	Gain-of-function	17349581;19296721;11751631;15093544;30341394;28572459;20570890;32792368;20147967;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)	Oncogenic			RMC-6236		MRTX-1133,Trametinib,ASP3082,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);36472553;33933896;25435214;24746704;23934108;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)										
GRCh37	KRAS	Missense	CRUK0666-SU_T1.R5	p.G12D	p.G12D	c.G35A	12	25398284	25398284	C	T	T	0.44705882352941206	LUAD	True	True	True	Gain-of-function	17349581;19296721;11751631;15093544;30341394;28572459;20570890;32792368;20147967;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)	Oncogenic			RMC-6236		MRTX-1133,Trametinib,ASP3082,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);36472553;33933896;25435214;24746704;23934108;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)										
GRCh37	KRAS	Missense	CRUK0666-SU_T1.R6	p.G12D	p.G12D	c.G35A	12	25398284	25398284	C	T	T	0.239005736137667	LUAD	True	True	True	Gain-of-function	17349581;19296721;11751631;15093544;30341394;28572459;20570890;32792368;20147967;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)	Oncogenic			RMC-6236		MRTX-1133,Trametinib,ASP3082,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);36472553;33933896;25435214;24746704;23934108;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)										
GRCh37	KRAS	Missense	CRUK0666-SU_FLN1	p.G12D	p.G12D	c.G35A	12	25398284	25398284	C	T	T	0.20960698689956303	LUAD	True	True	True	Gain-of-function	17349581;19296721;11751631;15093544;30341394;28572459;20570890;32792368;20147967;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)	Oncogenic			RMC-6236		MRTX-1133,Trametinib,ASP3082,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);36472553;33933896;25435214;24746704;23934108;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)										
GRCh37	KRAS	Missense	CRUK0667-SU_T1.R1	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.311004784688995	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0667-SU_T1.R2	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.51270207852194	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0667-SU_T1.R3	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.392504930966469	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0667-SU_T1.R4	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.325301204819277	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0667-SU_T1.R5	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.4840871021775539	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0667-SU_T1.R6	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.447463768115942	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0667-SU_T1.R7	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.38663967611336	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0667-SU_T1.R8	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.39589905362776	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0667-SU_FLN1	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.285992217898833	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0680-SU_T1.R1	p.G12S	p.G12S	c.G34A	12	25398285	25398285	C	T	T	0.43513513513513497	LUAD	True	True	True	Gain-of-function	28572459;25284075;26184075	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0680-SU_T1.R2	p.G12S	p.G12S	c.G34A	12	25398285	25398285	C	T	T	0.18930041152263397	LUAD	True	True	True	Gain-of-function	28572459;25284075;26184075	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0680-SU_T1.R3	p.G12S	p.G12S	c.G34A	12	25398285	25398285	C	T	T	0.518072289156627	LUAD	True	True	True	Gain-of-function	28572459;25284075;26184075	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0680-SU_T1.R4	p.G12S	p.G12S	c.G34A	12	25398285	25398285	C	T	T	0.17877094972067	LUAD	True	True	True	Gain-of-function	28572459;25284075;26184075	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0680-SU_T1.R5	p.G12S	p.G12S	c.G34A	12	25398285	25398285	C	T	T	0.47093023255814	LUAD	True	True	True	Gain-of-function	28572459;25284075;26184075	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	EGFR	In_Frame_Del	CRUK0684-SU_T1.R1			c.2234_2234delins-GGAATTAAGAGAAGC	7	55242464	55242464	A	-GGAATTAAGAGAAGC	-GGAATTAAGAGAAGC	0.163475699558174	LUAD	True	True	True	Likely Gain-of-function	15329413;18000506;15118125;34526717;19536777;18458038;15118073;22019513;23566546;23559152;24457318;22760226;23749122;17192902	Likely Oncogenic	Erlotinib,Osimertinib+Chemotherapy,Erlotinib+Ramucirumab,Afatinib,Gefitinib,Osimertinib,Dacomitinib	Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		22285168;27987585;29151359;37937763;31751012;30659024;23816960;22452895;25589191;20022809;19692680;21670455;22370314;31682542;20573926;29864379;28958502;37879444;37689979;38369013;31661465;34548309;30057690;34084213;38924756;34028784;37710001										
GRCh37	EGFR	In_Frame_Del	CRUK0684-SU_T1.R2			c.2234_2234delins-GGAATTAAGAGAAGC	7	55242464	55242464	A	-GGAATTAAGAGAAGC	-GGAATTAAGAGAAGC	0.190559440559441	LUAD	True	True	True	Likely Gain-of-function	15329413;18000506;15118125;34526717;19536777;18458038;15118073;22019513;23566546;23559152;24457318;22760226;23749122;17192902	Likely Oncogenic	Erlotinib,Osimertinib+Chemotherapy,Erlotinib+Ramucirumab,Afatinib,Gefitinib,Osimertinib,Dacomitinib	Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		22285168;27987585;29151359;37937763;31751012;30659024;23816960;22452895;25589191;20022809;19692680;21670455;22370314;31682542;20573926;29864379;28958502;37879444;37689979;38369013;31661465;34548309;30057690;34084213;38924756;34028784;37710001										
GRCh37	EGFR	In_Frame_Del	CRUK0684-SU_T1.R3			c.2234_2234delins-GGAATTAAGAGAAGC	7	55242464	55242464	A	-GGAATTAAGAGAAGC	-GGAATTAAGAGAAGC	0.12106918238993698	LUAD	True	True	True	Likely Gain-of-function	15329413;18000506;15118125;34526717;19536777;18458038;15118073;22019513;23566546;23559152;24457318;22760226;23749122;17192902	Likely Oncogenic	Erlotinib,Osimertinib+Chemotherapy,Erlotinib+Ramucirumab,Afatinib,Gefitinib,Osimertinib,Dacomitinib	Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		22285168;27987585;29151359;37937763;31751012;30659024;23816960;22452895;25589191;20022809;19692680;21670455;22370314;31682542;20573926;29864379;28958502;37879444;37689979;38369013;31661465;34548309;30057690;34084213;38924756;34028784;37710001										
GRCh37	EGFR	In_Frame_Del	CRUK0684-SU_T1.R4			c.2234_2234delins-GGAATTAAGAGAAGC	7	55242464	55242464	A	-GGAATTAAGAGAAGC	-GGAATTAAGAGAAGC	0.161993769470405	LUAD	True	True	True	Likely Gain-of-function	15329413;18000506;15118125;34526717;19536777;18458038;15118073;22019513;23566546;23559152;24457318;22760226;23749122;17192902	Likely Oncogenic	Erlotinib,Osimertinib+Chemotherapy,Erlotinib+Ramucirumab,Afatinib,Gefitinib,Osimertinib,Dacomitinib	Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		22285168;27987585;29151359;37937763;31751012;30659024;23816960;22452895;25589191;20022809;19692680;21670455;22370314;31682542;20573926;29864379;28958502;37879444;37689979;38369013;31661465;34548309;30057690;34084213;38924756;34028784;37710001										
GRCh37	KRAS	Missense	CRUK0687-SU_T1.R1	p.G60V	p.G60V	c.G179T	12	25380279	25380279	C	A	A	0.0569620253164557	LUAD	True	True	True	Likely Gain-of-function	27288520;24446311;34117033	Likely Oncogenic					Trametinib,Cobimetinib,Binimetinib			LEVEL_4	LEVEL_4		33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0687-SU_T1.R2	p.G60V	p.G60V	c.G179T	12	25380279	25380279	C	A	A	0.00364963503649635	LUAD	True	True	True	Likely Gain-of-function	27288520;24446311;34117033	Likely Oncogenic					Trametinib,Cobimetinib,Binimetinib			LEVEL_4	LEVEL_4		33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0704-SU_T2.R1	p.G13C	p.G13C	c.G37T	12	25398282	25398282	C	A	A	0.195704057279236	LUAD	True	True	True	Gain-of-function	28572459;21079152;25705018	Oncogenic					Trametinib,Cobimetinib,Binimetinib			LEVEL_4	LEVEL_4		33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0704-SU_T2.R2	p.G13C	p.G13C	c.G37T	12	25398282	25398282	C	A	A	0.162227602905569	LUAD	True	True	True	Gain-of-function	28572459;21079152;25705018	Oncogenic					Trametinib,Cobimetinib,Binimetinib			LEVEL_4	LEVEL_4		33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0704-SU_T2.R3	p.G13C	p.G13C	c.G37T	12	25398282	25398282	C	A	A	0.139841688654354	LUAD	True	True	True	Gain-of-function	28572459;21079152;25705018	Oncogenic					Trametinib,Cobimetinib,Binimetinib			LEVEL_4	LEVEL_4		33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0704-SU_T2.R4	p.G13C	p.G13C	c.G37T	12	25398282	25398282	C	A	A	0.11378555798687101	LUAD	True	True	True	Gain-of-function	28572459;21079152;25705018	Oncogenic					Trametinib,Cobimetinib,Binimetinib			LEVEL_4	LEVEL_4		33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0704-SU_T1.R3	p.G13C	p.G13C	c.G37T	12	25398282	25398282	C	A	A	0.35048231511253997	LUAD	True	True	True	Gain-of-function	28572459;21079152;25705018	Oncogenic					Trametinib,Cobimetinib,Binimetinib			LEVEL_4	LEVEL_4		33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0704-SU_T1.R4	p.G13C	p.G13C	c.G37T	12	25398282	25398282	C	A	A	0.236923076923077	LUAD	True	True	True	Gain-of-function	28572459;21079152;25705018	Oncogenic					Trametinib,Cobimetinib,Binimetinib			LEVEL_4	LEVEL_4		33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0704-SU_T1.R5	p.G13C	p.G13C	c.G37T	12	25398282	25398282	C	A	A	0.27857142857142897	LUAD	True	True	True	Gain-of-function	28572459;21079152;25705018	Oncogenic					Trametinib,Cobimetinib,Binimetinib			LEVEL_4	LEVEL_4		33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0704-SU_T1.R1	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.31331592689295	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0704-SU_T1.R2	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.258793969849246	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0738-SU_T1.R1	p.G12D	p.G12D	c.G35A	12	25398284	25398284	C	T	T	0.292626728110599	LUAD	True	True	True	Gain-of-function	17349581;19296721;11751631;15093544;30341394;28572459;20570890;32792368;20147967;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)	Oncogenic			RMC-6236		MRTX-1133,Trametinib,ASP3082,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);36472553;33933896;25435214;24746704;23934108;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)										
GRCh37	KRAS	Missense	CRUK0738-SU_T1.R2	p.G12D	p.G12D	c.G35A	12	25398284	25398284	C	T	T	0.275229357798165	LUAD	True	True	True	Gain-of-function	17349581;19296721;11751631;15093544;30341394;28572459;20570890;32792368;20147967;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)	Oncogenic			RMC-6236		MRTX-1133,Trametinib,ASP3082,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);36472553;33933896;25435214;24746704;23934108;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)										
GRCh37	KRAS	Missense	CRUK0738-SU_T1.R3	p.G12D	p.G12D	c.G35A	12	25398284	25398284	C	T	T	0.272727272727273	LUAD	True	True	True	Gain-of-function	17349581;19296721;11751631;15093544;30341394;28572459;20570890;32792368;20147967;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)	Oncogenic			RMC-6236		MRTX-1133,Trametinib,ASP3082,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);36472553;33933896;25435214;24746704;23934108;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)										
GRCh37	KRAS	Missense	CRUK0741-SU_T1.R1	p.G13C	p.G13C	c.G37T	12	25398282	25398282	C	A	A	0.19678714859437801	LUAD	True	True	True	Gain-of-function	28572459;21079152;25705018	Oncogenic					Trametinib,Cobimetinib,Binimetinib			LEVEL_4	LEVEL_4		33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0741-SU_T1.R2	p.G13C	p.G13C	c.G37T	12	25398282	25398282	C	A	A	0.0414201183431953	LUAD	True	True	True	Gain-of-function	28572459;21079152;25705018	Oncogenic					Trametinib,Cobimetinib,Binimetinib			LEVEL_4	LEVEL_4		33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0741-SU_T1.R3	p.G13C	p.G13C	c.G37T	12	25398282	25398282	C	A	A	0.40094339622641495	LUAD	True	True	True	Gain-of-function	28572459;21079152;25705018	Oncogenic					Trametinib,Cobimetinib,Binimetinib			LEVEL_4	LEVEL_4		33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0741-SU_T1.R4	p.G13C	p.G13C	c.G37T	12	25398282	25398282	C	A	A	0.23529411764705901	LUAD	True	True	True	Gain-of-function	28572459;21079152;25705018	Oncogenic					Trametinib,Cobimetinib,Binimetinib			LEVEL_4	LEVEL_4		33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0748-SU_LN2	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.22247191011235998	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0748-SU_T1.R1	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.452423698384201	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0748-SU_T1.R2	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.39852398523985205	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0748-SU_T1.R3	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.429752066115702	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0748-SU_T1.R4	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.37142857142857105	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0748-SU_T1.R5	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.4470108695652171	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0748-SU_T1.R6	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.35	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0748-SU_T1.R7	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.0904872389791183	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0748-SU_T1.R8	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.467874794069193	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0748-SU_FLN2	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.265861027190332	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0748-SU_FLN4	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.139705882352941	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0755-SU_T1.R1	p.G12D	p.G12D	c.G35A	12	25398284	25398284	C	T	T	0.14285714285714302	LUAD	True	True	True	Gain-of-function	17349581;19296721;11751631;15093544;30341394;28572459;20570890;32792368;20147967;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)	Oncogenic			RMC-6236		MRTX-1133,Trametinib,ASP3082,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);36472553;33933896;25435214;24746704;23934108;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)										
GRCh37	KRAS	Missense	CRUK0755-SU_T1.R2	p.G12D	p.G12D	c.G35A	12	25398284	25398284	C	T	T	0.36220472440944895	LUAD	True	True	True	Gain-of-function	17349581;19296721;11751631;15093544;30341394;28572459;20570890;32792368;20147967;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)	Oncogenic			RMC-6236		MRTX-1133,Trametinib,ASP3082,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);36472553;33933896;25435214;24746704;23934108;Nagashima et al. Abstract# 5735, AACR 2023.(https://aacrjournals.org/cancerres/article/83/7_Supplement/5735/722276)										
GRCh37	KRAS	Missense	CRUK0756-SU_T1.R1	p.G13C	p.G13C	c.G37T	12	25398282	25398282	C	A	A	0.283068783068783	LUAD	True	True	True	Gain-of-function	28572459;21079152;25705018	Oncogenic					Trametinib,Cobimetinib,Binimetinib			LEVEL_4	LEVEL_4		33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0756-SU_T1.R2	p.G13C	p.G13C	c.G37T	12	25398282	25398282	C	A	A	0.537878787878788	LUAD	True	True	True	Gain-of-function	28572459;21079152;25705018	Oncogenic					Trametinib,Cobimetinib,Binimetinib			LEVEL_4	LEVEL_4		33933896;25435214;24746704;23934108										
GRCh37	EGFR	Missense	CRUK0761-SU_T1.R1	p.L858R	p.L858R	c.T2573G	7	55259515	55259515	T	G	G	0.46595744680851103	LUAD	True	True	True	Gain-of-function	15329413;15118073;15118125;34526717	Oncogenic	Erlotinib,Osimertinib+Chemotherapy,Erlotinib+Ramucirumab,Afatinib,Gefitinib,Osimertinib,Dacomitinib	Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		22285168;27987585;29151359;37937763;31751012;30659024;23816960;22452895;25589191;20022809;19692680;21670455;22370314;31682542;20573926;29864379;28958502;37879444;37689979;38369013;31661465;34548309;30057690;34084213;38924756;34028784;37710001										
GRCh37	EGFR	Missense	CRUK0761-SU_T1.R2	p.L858R	p.L858R	c.T2573G	7	55259515	55259515	T	G	G	0.494553376906318	LUAD	True	True	True	Gain-of-function	15329413;15118073;15118125;34526717	Oncogenic	Erlotinib,Osimertinib+Chemotherapy,Erlotinib+Ramucirumab,Afatinib,Gefitinib,Osimertinib,Dacomitinib	Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		22285168;27987585;29151359;37937763;31751012;30659024;23816960;22452895;25589191;20022809;19692680;21670455;22370314;31682542;20573926;29864379;28958502;37879444;37689979;38369013;31661465;34548309;30057690;34084213;38924756;34028784;37710001										
GRCh37	EGFR	Missense	CRUK0761-SU_T1.R3	p.L858R	p.L858R	c.T2573G	7	55259515	55259515	T	G	G	0.47281323877068604	LUAD	True	True	True	Gain-of-function	15329413;15118073;15118125;34526717	Oncogenic	Erlotinib,Osimertinib+Chemotherapy,Erlotinib+Ramucirumab,Afatinib,Gefitinib,Osimertinib,Dacomitinib	Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		22285168;27987585;29151359;37937763;31751012;30659024;23816960;22452895;25589191;20022809;19692680;21670455;22370314;31682542;20573926;29864379;28958502;37879444;37689979;38369013;31661465;34548309;30057690;34084213;38924756;34028784;37710001										
GRCh37	EGFR	Missense	CRUK0761-SU_T1.R4	p.L858R	p.L858R	c.T2573G	7	55259515	55259515	T	G	G	0.432835820895522	LUAD	True	True	True	Gain-of-function	15329413;15118073;15118125;34526717	Oncogenic	Erlotinib,Osimertinib+Chemotherapy,Erlotinib+Ramucirumab,Afatinib,Gefitinib,Osimertinib,Dacomitinib	Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		22285168;27987585;29151359;37937763;31751012;30659024;23816960;22452895;25589191;20022809;19692680;21670455;22370314;31682542;20573926;29864379;28958502;37879444;37689979;38369013;31661465;34548309;30057690;34084213;38924756;34028784;37710001										
GRCh37	ERBB2	In_Frame_Ins	CRUK0762-SU_LN1	p.E770delinsEAYVM	p.E770delinsEAYVM	c.2310_2311insGCATACGTGATG	17	37880981	37880981	-	GCATACGTGATG	GCATACGTGATG	0.0949152542372881	LUAD	True	True	False	Gain-of-function	29967253;26559459	Oncogenic	Trastuzumab Deruxtecan	Ado-Trastuzumab Emtansine	Neratinib,Trastuzumab+Pertuzumab+Docetaxel					LEVEL_1	LEVEL_1		34534430;31588020;29989854;30206164;23220880;29420467;15059883;19934333;28959366;35073148										
GRCh37	ERBB2	In_Frame_Ins	CRUK0762-SU_LN2	p.E770delinsEAYVM	p.E770delinsEAYVM	c.2310_2311insGCATACGTGATG	17	37880981	37880981	-	GCATACGTGATG	GCATACGTGATG	0.0729166666666667	LUAD	True	True	False	Gain-of-function	29967253;26559459	Oncogenic	Trastuzumab Deruxtecan	Ado-Trastuzumab Emtansine	Neratinib,Trastuzumab+Pertuzumab+Docetaxel					LEVEL_1	LEVEL_1		34534430;31588020;29989854;30206164;23220880;29420467;15059883;19934333;28959366;35073148										
GRCh37	ERBB2	In_Frame_Ins	CRUK0762-SU_T1.R1	p.E770delinsEAYVM	p.E770delinsEAYVM	c.2310_2311insGCATACGTGATG	17	37880981	37880981	-	GCATACGTGATG	GCATACGTGATG	0.19327731092436998	LUAD	True	True	False	Gain-of-function	29967253;26559459	Oncogenic	Trastuzumab Deruxtecan	Ado-Trastuzumab Emtansine	Neratinib,Trastuzumab+Pertuzumab+Docetaxel					LEVEL_1	LEVEL_1		34534430;31588020;29989854;30206164;23220880;29420467;15059883;19934333;28959366;35073148										
GRCh37	ERBB2	In_Frame_Ins	CRUK0762-SU_T1.R2	p.E770delinsEAYVM	p.E770delinsEAYVM	c.2310_2311insGCATACGTGATG	17	37880981	37880981	-	GCATACGTGATG	GCATACGTGATG	0.20588235294117604	LUAD	True	True	False	Gain-of-function	29967253;26559459	Oncogenic	Trastuzumab Deruxtecan	Ado-Trastuzumab Emtansine	Neratinib,Trastuzumab+Pertuzumab+Docetaxel					LEVEL_1	LEVEL_1		34534430;31588020;29989854;30206164;23220880;29420467;15059883;19934333;28959366;35073148										
GRCh37	ERBB2	In_Frame_Ins	CRUK0762-SU_FLN1	p.E770delinsEAYVM	p.E770delinsEAYVM	c.2310_2311insGCATACGTGATG	17	37880981	37880981	-	GCATACGTGATG	GCATACGTGATG	0.0822784810126582	LUAD	True	True	False	Gain-of-function	29967253;26559459	Oncogenic	Trastuzumab Deruxtecan	Ado-Trastuzumab Emtansine	Neratinib,Trastuzumab+Pertuzumab+Docetaxel					LEVEL_1	LEVEL_1		34534430;31588020;29989854;30206164;23220880;29420467;15059883;19934333;28959366;35073148										
GRCh37	ERBB2	In_Frame_Ins	CRUK0762-SU_FLN2	p.E770delinsEAYVM	p.E770delinsEAYVM	c.2310_2311insGCATACGTGATG	17	37880981	37880981	-	GCATACGTGATG	GCATACGTGATG	0.0555555555555556	LUAD	True	True	False	Gain-of-function	29967253;26559459	Oncogenic	Trastuzumab Deruxtecan	Ado-Trastuzumab Emtansine	Neratinib,Trastuzumab+Pertuzumab+Docetaxel					LEVEL_1	LEVEL_1		34534430;31588020;29989854;30206164;23220880;29420467;15059883;19934333;28959366;35073148										
GRCh37	ERBB2	In_Frame_Ins	CRUK0762-SU_FLN3	p.E770delinsEAYVM	p.E770delinsEAYVM	c.2310_2311insGCATACGTGATG	17	37880981	37880981	-	GCATACGTGATG	GCATACGTGATG	0.0595238095238095	LUAD	True	True	False	Gain-of-function	29967253;26559459	Oncogenic	Trastuzumab Deruxtecan	Ado-Trastuzumab Emtansine	Neratinib,Trastuzumab+Pertuzumab+Docetaxel					LEVEL_1	LEVEL_1		34534430;31588020;29989854;30206164;23220880;29420467;15059883;19934333;28959366;35073148										
GRCh37	KRAS	Missense	CRUK0766-SU_T1.R1	p.G13C	p.G13C	c.G37T	12	25398282	25398282	C	A	A	0.22535211267605604	LUAD	True	True	True	Gain-of-function	28572459;21079152;25705018	Oncogenic					Trametinib,Cobimetinib,Binimetinib			LEVEL_4	LEVEL_4		33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0766-SU_T1.R2	p.G13C	p.G13C	c.G37T	12	25398282	25398282	C	A	A	0.41686746987951795	LUAD	True	True	True	Gain-of-function	28572459;21079152;25705018	Oncogenic					Trametinib,Cobimetinib,Binimetinib			LEVEL_4	LEVEL_4		33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0766-SU_FLN1	p.G13C	p.G13C	c.G37T	12	25398282	25398282	C	A	A	0.230046948356808	LUAD	True	True	True	Gain-of-function	28572459;21079152;25705018	Oncogenic					Trametinib,Cobimetinib,Binimetinib			LEVEL_4	LEVEL_4		33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0775-SU_T1.R1	p.Q61H	p.Q61H	c.A183C	12	25380275	25380275	T	G	G	0.26640926640926604	LUAD	True	True	True	Gain-of-function	24651010;28572459;25705018;34117033;20147967;21993244	Oncogenic					Trametinib,Cobimetinib,Binimetinib			LEVEL_4	LEVEL_4		33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0775-SU_T1.R2	p.Q61H	p.Q61H	c.A183C	12	25380275	25380275	T	G	G	0.263681592039801	LUAD	True	True	True	Gain-of-function	24651010;28572459;25705018;34117033;20147967;21993244	Oncogenic					Trametinib,Cobimetinib,Binimetinib			LEVEL_4	LEVEL_4		33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0788-SU_T1.R1	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.15753424657534199	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0788-SU_T1.R2	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.036697247706422007	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0788-SU_T1.R3	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.12751677852349	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0788-SU_T1.R4	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.178571428571429	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0788-SU_T1.R5	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.263285024154589	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0788-SU_T1.R6	p.G12V	p.G12V	c.G35T	12	25398284	25398284	C	A	A	0.0334928229665072	LUAD	True	True	True	Gain-of-function	20516123;20949621;30341394;28572459;25359494;20570890;12957286;20147967	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	BRAF	Missense	CRUK0788-SU_T1.R1	p.D594N	p.D594N	c.G1780A	7	140453155	140453155	C	T	T	0.16428571428571398	LUAD	True	True	True	Gain-of-function	23833300;26498038;36136993;28783719;22798288;28947956	Oncogenic																					
GRCh37	BRAF	Missense	CRUK0788-SU_T1.R2	p.D594N	p.D594N	c.G1780A	7	140453155	140453155	C	T	T	0.0374331550802139	LUAD	True	True	True	Gain-of-function	23833300;26498038;36136993;28783719;22798288;28947956	Oncogenic																					
GRCh37	BRAF	Missense	CRUK0788-SU_T1.R1	p.G469A	p.G469A	c.G1406C	7	140481402	140481402	C	G	G	0.0304709141274238	LUAD	True	True	True	Gain-of-function	20179705;26343582;12068308;29247021;28783719;22510884;22773810;16439621;31924734;23833300;31515458;29320312;32540409	Oncogenic					Plixorafenib			LEVEL_4	LEVEL_4		26466569;28659148;28783719;30559419;Janku et al. Abstract# B176, AACR-NCI-EORTC 2017.(http://mct.aacrjournals.org/content/17/1_Supplement/B176);Fuente et al. Abstract# 3006, J. Clin. Oncol. 2023, Vol 41, Suppl 16.(https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.3006)										
GRCh37	BRAF	Missense	CRUK0788-SU_T1.R2	p.G469A	p.G469A	c.G1406C	7	140481402	140481402	C	G	G	0.00635593220338983	LUAD	True	True	True	Gain-of-function	20179705;26343582;12068308;29247021;28783719;22510884;22773810;16439621;31924734;23833300;31515458;29320312;32540409	Oncogenic					Plixorafenib			LEVEL_4	LEVEL_4		26466569;28659148;28783719;30559419;Janku et al. Abstract# B176, AACR-NCI-EORTC 2017.(http://mct.aacrjournals.org/content/17/1_Supplement/B176);Fuente et al. Abstract# 3006, J. Clin. Oncol. 2023, Vol 41, Suppl 16.(https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.3006)										
GRCh37	BRAF	Missense	CRUK0788-SU_T1.R3	p.G469A	p.G469A	c.G1406C	7	140481402	140481402	C	G	G	0.0190930787589499	LUAD	True	True	True	Gain-of-function	20179705;26343582;12068308;29247021;28783719;22510884;22773810;16439621;31924734;23833300;31515458;29320312;32540409	Oncogenic					Plixorafenib			LEVEL_4	LEVEL_4		26466569;28659148;28783719;30559419;Janku et al. Abstract# B176, AACR-NCI-EORTC 2017.(http://mct.aacrjournals.org/content/17/1_Supplement/B176);Fuente et al. Abstract# 3006, J. Clin. Oncol. 2023, Vol 41, Suppl 16.(https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.3006)										
GRCh37	BRAF	Missense	CRUK0788-SU_T1.R4	p.G469A	p.G469A	c.G1406C	7	140481402	140481402	C	G	G	0.008830022075055191	LUAD	True	True	True	Gain-of-function	20179705;26343582;12068308;29247021;28783719;22510884;22773810;16439621;31924734;23833300;31515458;29320312;32540409	Oncogenic					Plixorafenib			LEVEL_4	LEVEL_4		26466569;28659148;28783719;30559419;Janku et al. Abstract# B176, AACR-NCI-EORTC 2017.(http://mct.aacrjournals.org/content/17/1_Supplement/B176);Fuente et al. Abstract# 3006, J. Clin. Oncol. 2023, Vol 41, Suppl 16.(https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.3006)										
GRCh37	BRAF	Missense	CRUK0788-SU_T1.R5	p.G469A	p.G469A	c.G1406C	7	140481402	140481402	C	G	G	0.00251256281407035	LUAD	True	True	True	Gain-of-function	20179705;26343582;12068308;29247021;28783719;22510884;22773810;16439621;31924734;23833300;31515458;29320312;32540409	Oncogenic					Plixorafenib			LEVEL_4	LEVEL_4		26466569;28659148;28783719;30559419;Janku et al. Abstract# B176, AACR-NCI-EORTC 2017.(http://mct.aacrjournals.org/content/17/1_Supplement/B176);Fuente et al. Abstract# 3006, J. Clin. Oncol. 2023, Vol 41, Suppl 16.(https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.3006)										
GRCh37	BRAF	Missense	CRUK0788-SU_T1.R6	p.G469A	p.G469A	c.G1406C	7	140481402	140481402	C	G	G	0.00271739130434783	LUAD	True	True	True	Gain-of-function	20179705;26343582;12068308;29247021;28783719;22510884;22773810;16439621;31924734;23833300;31515458;29320312;32540409	Oncogenic					Plixorafenib			LEVEL_4	LEVEL_4		26466569;28659148;28783719;30559419;Janku et al. Abstract# B176, AACR-NCI-EORTC 2017.(http://mct.aacrjournals.org/content/17/1_Supplement/B176);Fuente et al. Abstract# 3006, J. Clin. Oncol. 2023, Vol 41, Suppl 16.(https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.3006)										
GRCh37	KRAS	Missense	CRUK0810-SU_LN1	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.230125523012552	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0810-SU_LN2	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.35964912280701794	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0810-SU_LN3	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.0793201133144476	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0810-SU_T1.R1	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.16621983914209099	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0810-SU_T1.R2	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.25974025974026	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0810-SU_T1.R3	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.21474358974358998	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0810-SU_T1.R4	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.24907063197026	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0810-SU_T1.R5	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.31531531531531504	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0810-SU_T1.R6	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.237603305785124	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0810-SU_T1.R7	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.2575	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0810-SU_T1.R8	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.19623655913978502	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0810-BR_LN1	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.163636363636364	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0810-SU_FLN1	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.268733850129199	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0864-SU_T1.R1	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.283116883116883	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0864-SU_T1.R2	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.446969696969697	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0864-SU_T1.R3	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.44782608695652204	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0881-SU_T1.R1	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.24418604651162804	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0881-SU_T1.R2	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.4957264957264961	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0881-SU_T1.R3	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.5333333333333329	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0881-SU_T1.R4	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.35258358662614003	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0881-SU_T1.R5	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.3909774436090229	LUAD	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	BRAF	Missense	CRUK0881-SU_T2.R1	p.G466V	p.G466V	c.G1397T	7	140481411	140481411	C	A	A	0.324712643678161	LUAD	True	True	True	Gain-of-function	30104724;31959346;26498038;22649091;26090892;16364920;27523909;28783719;15046639;28481359;16439621;31924734;31515458;24202393;30559419;15035987	Oncogenic																					
GRCh37	BRAF	Missense	CRUK0881-SU_T2.R2	p.G466V	p.G466V	c.G1397T	7	140481411	140481411	C	A	A	0.10067114093959699	LUAD	True	True	True	Gain-of-function	30104724;31959346;26498038;22649091;26090892;16364920;27523909;28783719;15046639;28481359;16439621;31924734;31515458;24202393;30559419;15035987	Oncogenic																					
GRCh37	KRAS	Missense	CRUK0893-SU_T1.R1	p.G12A	p.G12A	c.G35C	12	25398284	25398284	C	G	G	0.0928381962864721	LUAD	True	True	True	Gain-of-function	30341394;26662311;26037647;23182985	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0893-SU_T1.R2	p.G12A	p.G12A	c.G35C	12	25398284	25398284	C	G	G	0.19370460048426102	LUAD	True	True	True	Gain-of-function	30341394;26662311;26037647;23182985	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0067-SU_T1.R1	p.R68S	p.R68S	c.G204C	12	25380254	25380254	C	G	G	0.138666666666667	LUSC	True	True	True	Likely Gain-of-function	34117033	Likely Oncogenic					Trametinib,Cobimetinib,Binimetinib			LEVEL_4	LEVEL_4		33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0067-SU_T1.R3	p.R68S	p.R68S	c.G204C	12	25380254	25380254	C	G	G	0.291005291005291	LUSC	True	True	True	Likely Gain-of-function	34117033	Likely Oncogenic					Trametinib,Cobimetinib,Binimetinib			LEVEL_4	LEVEL_4		33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0069-SU_T1.R1	p.G12S	p.G12S	c.G34A	12	25398285	25398285	C	T	T	0.140625	LUSC	True	True	True	Gain-of-function	28572459;25284075;26184075	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0069-SU_T1.R2	p.G12S	p.G12S	c.G34A	12	25398285	25398285	C	T	T	0.0456692913385827	LUSC	True	True	True	Gain-of-function	28572459;25284075;26184075	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0069-SU_T1.R3	p.G12S	p.G12S	c.G34A	12	25398285	25398285	C	T	T	0.0877598152424942	LUSC	True	True	True	Gain-of-function	28572459;25284075;26184075	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0069-SU_T1.R4	p.G12S	p.G12S	c.G34A	12	25398285	25398285	C	T	T	0.10419906687402801	LUSC	True	True	True	Gain-of-function	28572459;25284075;26184075	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0069-SU_T1.R5	p.G12S	p.G12S	c.G34A	12	25398285	25398285	C	T	T	0.0979498861047836	LUSC	True	True	True	Gain-of-function	28572459;25284075;26184075	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0223-SU_T1.R1	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.152284263959391	LUSC	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0223-SU_T1.R2	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.205014749262537	LUSC	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0250-SU_T1.R1	p.G12A	p.G12A	c.G35C	12	25398284	25398284	C	G	G	0.18890356671070002	LUSC	True	True	True	Gain-of-function	30341394;26662311;26037647;23182985	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0250-SU_T1.R2	p.G12A	p.G12A	c.G35C	12	25398284	25398284	C	G	G	0.27972027972028	LUSC	True	True	True	Gain-of-function	30341394;26662311;26037647;23182985	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0250-BR_T1.FR1	p.G12A	p.G12A	c.G35C	12	25398284	25398284	C	G	G	0.325536062378168	LUSC	True	True	True	Gain-of-function	30341394;26662311;26037647;23182985	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	EGFR	In_Frame_Del	CRUK0331-SU_T1.R1			c.2235_2235delins-GAATTAAGA	7	55242465	55242465	G	-GAATTAAGA	-GAATTAAGA	0.14599824098504802	LUSC	True	True	True	Likely Gain-of-function	15329413;18000506;15118125;34526717;19536777;18458038;15118073;22019513;23566546;23559152;24457318;22760226;23749122;17192902	Likely Oncogenic	Erlotinib,Osimertinib+Chemotherapy,Erlotinib+Ramucirumab,Afatinib,Gefitinib,Osimertinib,Dacomitinib	Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		22285168;27987585;29151359;37937763;31751012;30659024;23816960;22452895;25589191;20022809;19692680;21670455;22370314;31682542;20573926;29864379;28958502;37879444;37689979;38369013;31661465;34548309;30057690;34084213;38924756;34028784;37710001										
GRCh37	EGFR	In_Frame_Del	CRUK0331-SU_T1.R2			c.2235_2235delins-GAATTAAGA	7	55242465	55242465	G	-GAATTAAGA	-GAATTAAGA	0.14833948339483402	LUSC	True	True	True	Likely Gain-of-function	15329413;18000506;15118125;34526717;19536777;18458038;15118073;22019513;23566546;23559152;24457318;22760226;23749122;17192902	Likely Oncogenic	Erlotinib,Osimertinib+Chemotherapy,Erlotinib+Ramucirumab,Afatinib,Gefitinib,Osimertinib,Dacomitinib	Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		22285168;27987585;29151359;37937763;31751012;30659024;23816960;22452895;25589191;20022809;19692680;21670455;22370314;31682542;20573926;29864379;28958502;37879444;37689979;38369013;31661465;34548309;30057690;34084213;38924756;34028784;37710001										
GRCh37	EGFR	In_Frame_Del	CRUK0331-SU_T1.R3			c.2235_2235delins-GAATTAAGA	7	55242465	55242465	G	-GAATTAAGA	-GAATTAAGA	0.10796074154852801	LUSC	True	True	True	Likely Gain-of-function	15329413;18000506;15118125;34526717;19536777;18458038;15118073;22019513;23566546;23559152;24457318;22760226;23749122;17192902	Likely Oncogenic	Erlotinib,Osimertinib+Chemotherapy,Erlotinib+Ramucirumab,Afatinib,Gefitinib,Osimertinib,Dacomitinib	Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		22285168;27987585;29151359;37937763;31751012;30659024;23816960;22452895;25589191;20022809;19692680;21670455;22370314;31682542;20573926;29864379;28958502;37879444;37689979;38369013;31661465;34548309;30057690;34084213;38924756;34028784;37710001										
GRCh37	EGFR	In_Frame_Del	CRUK0331-SU_T1.R4			c.2235_2235delins-GAATTAAGA	7	55242465	55242465	G	-GAATTAAGA	-GAATTAAGA	0.127450980392157	LUSC	True	True	True	Likely Gain-of-function	15329413;18000506;15118125;34526717;19536777;18458038;15118073;22019513;23566546;23559152;24457318;22760226;23749122;17192902	Likely Oncogenic	Erlotinib,Osimertinib+Chemotherapy,Erlotinib+Ramucirumab,Afatinib,Gefitinib,Osimertinib,Dacomitinib	Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		22285168;27987585;29151359;37937763;31751012;30659024;23816960;22452895;25589191;20022809;19692680;21670455;22370314;31682542;20573926;29864379;28958502;37879444;37689979;38369013;31661465;34548309;30057690;34084213;38924756;34028784;37710001										
GRCh37	EGFR	In_Frame_Del	CRUK0331-SU_T1.R5			c.2235_2235delins-GAATTAAGA	7	55242465	55242465	G	-GAATTAAGA	-GAATTAAGA	0.0906148867313916	LUSC	True	True	True	Likely Gain-of-function	15329413;18000506;15118125;34526717;19536777;18458038;15118073;22019513;23566546;23559152;24457318;22760226;23749122;17192902	Likely Oncogenic	Erlotinib,Osimertinib+Chemotherapy,Erlotinib+Ramucirumab,Afatinib,Gefitinib,Osimertinib,Dacomitinib	Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		22285168;27987585;29151359;37937763;31751012;30659024;23816960;22452895;25589191;20022809;19692680;21670455;22370314;31682542;20573926;29864379;28958502;37879444;37689979;38369013;31661465;34548309;30057690;34084213;38924756;34028784;37710001										
GRCh37	EGFR	In_Frame_Del	CRUK0331-SU_T1.R6			c.2235_2235delins-GAATTAAGA	7	55242465	55242465	G	-GAATTAAGA	-GAATTAAGA	0.153259949195597	LUSC	True	True	True	Likely Gain-of-function	15329413;18000506;15118125;34526717;19536777;18458038;15118073;22019513;23566546;23559152;24457318;22760226;23749122;17192902	Likely Oncogenic	Erlotinib,Osimertinib+Chemotherapy,Erlotinib+Ramucirumab,Afatinib,Gefitinib,Osimertinib,Dacomitinib	Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		22285168;27987585;29151359;37937763;31751012;30659024;23816960;22452895;25589191;20022809;19692680;21670455;22370314;31682542;20573926;29864379;28958502;37879444;37689979;38369013;31661465;34548309;30057690;34084213;38924756;34028784;37710001										
GRCh37	EGFR	In_Frame_Del	CRUK0331-SU_T1.R7			c.2235_2235delins-GAATTAAGA	7	55242465	55242465	G	-GAATTAAGA	-GAATTAAGA	0.14210526315789498	LUSC	True	True	True	Likely Gain-of-function	15329413;18000506;15118125;34526717;19536777;18458038;15118073;22019513;23566546;23559152;24457318;22760226;23749122;17192902	Likely Oncogenic	Erlotinib,Osimertinib+Chemotherapy,Erlotinib+Ramucirumab,Afatinib,Gefitinib,Osimertinib,Dacomitinib	Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		22285168;27987585;29151359;37937763;31751012;30659024;23816960;22452895;25589191;20022809;19692680;21670455;22370314;31682542;20573926;29864379;28958502;37879444;37689979;38369013;31661465;34548309;30057690;34084213;38924756;34028784;37710001										
GRCh37	KRAS	Missense	CRUK0334-SU_T1.R1	p.Q61R	p.Q61R	c.A182G	12	25380276	25380276	T	C	C	0.21538461538461498	LUSC	True	True	True	Gain-of-function	30341394;28572459;34117033;25437878	Oncogenic					Trametinib,Cobimetinib,Binimetinib			LEVEL_4	LEVEL_4		33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0334-SU_T1.R2	p.Q61R	p.Q61R	c.A182G	12	25380276	25380276	T	C	C	0.0919540229885057	LUSC	True	True	True	Gain-of-function	30341394;28572459;34117033;25437878	Oncogenic					Trametinib,Cobimetinib,Binimetinib			LEVEL_4	LEVEL_4		33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0467-SU_T1.R1	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.0144665461121157	LUSC	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0467-SU_T1.R2	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.185692541856925	LUSC	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0467-BP_T1.R1	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.40564826700898604	LUSC	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0467-BR_T1.R1	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.14027149321267002	LUSC	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0467-SU_FLN1	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.137203166226913	LUSC	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0488-SU_T1.R1	p.G12A	p.G12A	c.G35C	12	25398284	25398284	C	G	G	0.0953488372093023	LUSC	True	True	True	Gain-of-function	30341394;26662311;26037647;23182985	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0488-SU_T1.R2	p.G12A	p.G12A	c.G35C	12	25398284	25398284	C	G	G	0.28721174004192895	LUSC	True	True	True	Gain-of-function	30341394;26662311;26037647;23182985	Oncogenic			RMC-6236		Trametinib,Cobimetinib,Binimetinib			LEVEL_3A	LEVEL_3A		38593348;Koltun et al. Abstract# 3597, AACR 2022.(https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320);Arbour, KC. et al., Abstract#6520, Annals of Oncol., 2023.(https://www.annalsofoncology.org/article/S0923-7534%2823%2902675-3/fulltext);Singh et al. Abstract  # 3597, AACR 2022.(https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_Singh.pdf);33933896;25435214;24746704;23934108										
GRCh37	EGFR	In_Frame_Del	CRUK0528-SU_T1.R1			c.1956_1956delins-GCC	7	55240712	55240712	G	-GCC	-GCC	0.15844544095665197	LUSC	True	True	True	Likely Gain-of-function	15329413;18000506;15118125;34526717;19536777;18458038;15118073;22019513;23566546;23559152;24457318;22760226;23749122;17192902	Likely Oncogenic	Erlotinib,Osimertinib+Chemotherapy,Erlotinib+Ramucirumab,Afatinib,Gefitinib,Osimertinib,Dacomitinib	Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		22285168;27987585;29151359;37937763;31751012;30659024;23816960;22452895;25589191;20022809;19692680;21670455;22370314;31682542;20573926;29864379;28958502;37879444;37689979;38369013;31661465;34548309;30057690;34084213;38924756;34028784;37710001										
GRCh37	EGFR	In_Frame_Del	CRUK0528-SU_T1.R2			c.1956_1956delins-GCC	7	55240712	55240712	G	-GCC	-GCC	0.16462346760070098	LUSC	True	True	True	Likely Gain-of-function	15329413;18000506;15118125;34526717;19536777;18458038;15118073;22019513;23566546;23559152;24457318;22760226;23749122;17192902	Likely Oncogenic	Erlotinib,Osimertinib+Chemotherapy,Erlotinib+Ramucirumab,Afatinib,Gefitinib,Osimertinib,Dacomitinib	Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		22285168;27987585;29151359;37937763;31751012;30659024;23816960;22452895;25589191;20022809;19692680;21670455;22370314;31682542;20573926;29864379;28958502;37879444;37689979;38369013;31661465;34548309;30057690;34084213;38924756;34028784;37710001										
GRCh37	EGFR	In_Frame_Del	CRUK0528-SU_T1.R3			c.1956_1956delins-GCC	7	55240712	55240712	G	-GCC	-GCC	0.179078014184397	LUSC	True	True	True	Likely Gain-of-function	15329413;18000506;15118125;34526717;19536777;18458038;15118073;22019513;23566546;23559152;24457318;22760226;23749122;17192902	Likely Oncogenic	Erlotinib,Osimertinib+Chemotherapy,Erlotinib+Ramucirumab,Afatinib,Gefitinib,Osimertinib,Dacomitinib	Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		22285168;27987585;29151359;37937763;31751012;30659024;23816960;22452895;25589191;20022809;19692680;21670455;22370314;31682542;20573926;29864379;28958502;37879444;37689979;38369013;31661465;34548309;30057690;34084213;38924756;34028784;37710001										
GRCh37	EGFR	In_Frame_Del	CRUK0528-SU_FLN1			c.1956_1956delins-GCC	7	55240712	55240712	G	-GCC	-GCC	0.125570776255708	LUSC	True	True	True	Likely Gain-of-function	15329413;18000506;15118125;34526717;19536777;18458038;15118073;22019513;23566546;23559152;24457318;22760226;23749122;17192902	Likely Oncogenic	Erlotinib,Osimertinib+Chemotherapy,Erlotinib+Ramucirumab,Afatinib,Gefitinib,Osimertinib,Dacomitinib	Amivantamab+Chemotherapy	Patritumab Deruxtecan,Amivantamab+Lazertinib					LEVEL_1	LEVEL_1		22285168;27987585;29151359;37937763;31751012;30659024;23816960;22452895;25589191;20022809;19692680;21670455;22370314;31682542;20573926;29864379;28958502;37879444;37689979;38369013;31661465;34548309;30057690;34084213;38924756;34028784;37710001										
GRCh37	KRAS	Missense	CRUK0549-SU_T1.R1	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.48433420365535207	LUSC	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0549-SU_T1.R2	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.24144869215291798	LUSC	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0549-SU_T1.R3	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.654171704957678	LUSC	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0549-SU_T1.R4	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.0586510263929619	LUSC	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0549-SU_T1.R5	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.706858407079646	LUSC	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0549-SU_T1.R6	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.24077669902912602	LUSC	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0549-SU_T1.R7	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.526166902404526	LUSC	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	KRAS	Missense	CRUK0549-SU_T1.R8	p.G12C	p.G12C	c.G34T	12	25398285	25398285	C	A	A	0.317415730337079	LUSC	True	True	True	Gain-of-function	25705018;38096473;24256730;28572459;16051643;32792368;26841430;Fakih et al. Abstract# 3003, ASCO 2019.(https://meetinglibrary.asco.org/record/172411/abstract)	Oncogenic	Sotorasib,Adagrasib			Adagrasib+Cetuximab,Adagrasib+Panitumumab,Sotorasib+Cetuximab,Sotorasib+Panitumumab	Trametinib,Cobimetinib,Binimetinib			LEVEL_1	LEVEL_1		38157806;34096690;32955176;37098232;36764316;35658005;Gadgeel, S. et al., Abstract# MA06.04, Journal of Thoracic Oncology Vol. 18.(https://www.jto.org/article/S1556-0864%2823%2900954-1/fulltext);38587856;37870968;36546659;38177853;33933896;25435214;24746704;23934108										
GRCh37	ERBB2	Missense	CRUK0549-SU_T1.R1	p.S310Y	p.S310Y	c.C929A	17	37868208	37868208	C	A	A	0.34261241970021394	LUSC	True	True	True	Gain-of-function	29967253;22908275;24997986;29420467	Oncogenic	Trastuzumab Deruxtecan	Ado-Trastuzumab Emtansine	Neratinib,Trastuzumab+Pertuzumab+Docetaxel					LEVEL_1	LEVEL_1		34534430;31588020;29989854;30206164;23220880;29420467;15059883;19934333;28959366;35073148										
GRCh37	ERBB2	Missense	CRUK0549-SU_T1.R2	p.S310Y	p.S310Y	c.C929A	17	37868208	37868208	C	A	A	0.251402918069585	LUSC	True	True	True	Gain-of-function	29967253;22908275;24997986;29420467	Oncogenic	Trastuzumab Deruxtecan	Ado-Trastuzumab Emtansine	Neratinib,Trastuzumab+Pertuzumab+Docetaxel					LEVEL_1	LEVEL_1		34534430;31588020;29989854;30206164;23220880;29420467;15059883;19934333;28959366;35073148										
GRCh37	ERBB2	Missense	CRUK0549-SU_T1.R3	p.S310Y	p.S310Y	c.C929A	17	37868208	37868208	C	A	A	0.307692307692308	LUSC	True	True	True	Gain-of-function	29967253;22908275;24997986;29420467	Oncogenic	Trastuzumab Deruxtecan	Ado-Trastuzumab Emtansine	Neratinib,Trastuzumab+Pertuzumab+Docetaxel					LEVEL_1	LEVEL_1		34534430;31588020;29989854;30206164;23220880;29420467;15059883;19934333;28959366;35073148										
GRCh37	ERBB2	Missense	CRUK0549-SU_T1.R4	p.S310Y	p.S310Y	c.C929A	17	37868208	37868208	C	A	A	0.0148936170212766	LUSC	True	True	True	Gain-of-function	29967253;22908275;24997986;29420467	Oncogenic	Trastuzumab Deruxtecan	Ado-Trastuzumab Emtansine	Neratinib,Trastuzumab+Pertuzumab+Docetaxel					LEVEL_1	LEVEL_1		34534430;31588020;29989854;30206164;23220880;29420467;15059883;19934333;28959366;35073148										
GRCh37	ERBB2	Missense	CRUK0549-SU_T1.R5	p.S310Y	p.S310Y	c.C929A	17	37868208	37868208	C	A	A	0.328516377649326	LUSC	True	True	True	Gain-of-function	29967253;22908275;24997986;29420467	Oncogenic	Trastuzumab Deruxtecan	Ado-Trastuzumab Emtansine	Neratinib,Trastuzumab+Pertuzumab+Docetaxel					LEVEL_1	LEVEL_1		34534430;31588020;29989854;30206164;23220880;29420467;15059883;19934333;28959366;35073148										
GRCh37	ERBB2	Missense	CRUK0549-SU_T1.R6	p.S310Y	p.S310Y	c.C929A	17	37868208	37868208	C	A	A	0.23134328358209	LUSC	True	True	True	Gain-of-function	29967253;22908275;24997986;29420467	Oncogenic	Trastuzumab Deruxtecan	Ado-Trastuzumab Emtansine	Neratinib,Trastuzumab+Pertuzumab+Docetaxel					LEVEL_1	LEVEL_1		34534430;31588020;29989854;30206164;23220880;29420467;15059883;19934333;28959366;35073148										
GRCh37	ERBB2	Missense	CRUK0549-SU_T1.R7	p.S310Y	p.S310Y	c.C929A	17	37868208	37868208	C	A	A	0.18245967741935504	LUSC	True	True	True	Gain-of-function	29967253;22908275;24997986;29420467	Oncogenic	Trastuzumab Deruxtecan	Ado-Trastuzumab Emtansine	Neratinib,Trastuzumab+Pertuzumab+Docetaxel					LEVEL_1	LEVEL_1		34534430;31588020;29989854;30206164;23220880;29420467;15059883;19934333;28959366;35073148										
GRCh37	ERBB2	Missense	CRUK0549-SU_T1.R8	p.S310Y	p.S310Y	c.C929A	17	37868208	37868208	C	A	A	0.0535714285714286	LUSC	True	True	True	Gain-of-function	29967253;22908275;24997986;29420467	Oncogenic	Trastuzumab Deruxtecan	Ado-Trastuzumab Emtansine	Neratinib,Trastuzumab+Pertuzumab+Docetaxel					LEVEL_1	LEVEL_1		34534430;31588020;29989854;30206164;23220880;29420467;15059883;19934333;28959366;35073148										
GRCh37	BRAF	Missense	CRUK0584-SU_T1.R1	p.T599S	p.T599S	c.A1795T	7	140453140	140453140	T	A	A	0.00671140939597315	LUSC	True	True	False	Likely Gain-of-function	19206169;25120313;33019809	Likely Oncogenic																					
GRCh37	BRAF	Missense	CRUK0584-SU_T1.R2	p.T599S	p.T599S	c.A1795T	7	140453140	140453140	T	A	A	0.0663265306122449	LUSC	True	True	False	Likely Gain-of-function	19206169;25120313;33019809	Likely Oncogenic																					
GRCh37	BRAF	Missense	CRUK0584-BR_FLN1	p.T599S	p.T599S	c.A1795T	7	140453140	140453140	T	A	A	0.154471544715447	LUSC	True	True	False	Likely Gain-of-function	19206169;25120313;33019809	Likely Oncogenic																					
GRCh37	BRAF	Missense	CRUK0584-SU_FLN1	p.T599S	p.T599S	c.A1795T	7	140453140	140453140	T	A	A	0.132743362831858	LUSC	True	True	False	Likely Gain-of-function	19206169;25120313;33019809	Likely Oncogenic																					
